{
  "letters": 541365,
  "pages": 131,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Incyte Corporation",
    "major_industry": "Pharmaceuticals",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 1,
          "title": "Annual Report Form 10-K for Incyte Corporation",
          "data": [
            {
              "key": "Company Name",
              "value": "INCYTE CORPORATION"
            },
            {
              "key": "Form Type",
              "value": "10-K"
            },
            {
              "key": "Fiscal Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Market Value of Common Stock",
              "value": "$14.2 billion"
            },
            {
              "key": "Shares Outstanding",
              "value": "222,965,018"
            },
            {
              "key": "Proxy Statement Reference",
              "value": "Proxy Statement to be filed for the 2023 Annual Meeting of Stockholders on June 14, 2023"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 43,
          "title": "Regulatory and Competitive Risks Faced by the Company",
          "data": [
            {
              "key": "Sunshine Provisions Compliance Risk",
              "value": "The need to comply with the Physician Payment Sunshine provisions and similar laws may incur significant costs and potential penalties."
            },
            {
              "key": "Competition",
              "value": "The presence of competing products may reduce sales and impact financial performance."
            },
            {
              "key": "Generic Competition",
              "value": "The ability of generic manufacturers to challenge patents and produce competing products may significantly affect market position."
            },
            {
              "key": "JAKAFI Patent Litigation",
              "value": "The ongoing and potential challenges against patents covering JAKAFI introduce a significant risk to its market exclusivity."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 56,
          "title": "Acquisition of ARIAD's European Operations",
          "data": [
            {
              "key": "Acquisition Date",
              "value": "June 2016"
            },
            {
              "key": "Context",
              "value": "We completed the acquisition of the European operations of ARIAD."
            },
            {
              "key": "Impact of the Acquisition",
              "value": "Significant expansion of operations in Europe."
            },
            {
              "key": "Risks Identified",
              "value": "Possibility of not realizing anticipated benefits, integration issues, potential for unknown liabilities."
            },
            {
              "key": "Financial Risks",
              "value": "Recorded unrealized losses related to investments in collaboration partners."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 70,
          "title": "License Agreements and Acquisitions",
          "data": [
            {
              "key": "Innovent Milestone Recognized",
              "value": "$5.0 million milestone under collaboration agreement"
            },
            {
              "key": "Lilly Milestone Recognized",
              "value": "$70.0 million for OLUMIANT approval"
            },
            {
              "key": "Maruho Strategic Alliance Agreement",
              "value": "Collaboration for ruxolitinib cream in Japan"
            },
            {
              "key": "Novartis Regulatory Milestones",
              "value": "$15.0 million and $45.0 million for marketing authorization and approval"
            },
            {
              "key": "Villaris Acquisition",
              "value": "Acquired Villaris Therapeutics, Inc. for $70 million upfront"
            },
            {
              "key": "CMS Aesthetics Limited Collaboration",
              "value": "Collaboration for ruxolitinib cream with $30.0 million upfront"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 82,
          "title": "Valuation of acquisition-related contingent consideration liability",
          "data": [
            {
              "key": "Description",
              "value": "The Company’s acquisition-related contingent consideration liability consists of certain future royalty obligations on future net revenues of ICLUSIG."
            },
            {
              "key": "Remeasurement",
              "value": "The liability is remeasured to its estimated fair value each reporting period, with changes in fair value recorded in the consolidated statements of operations."
            },
            {
              "key": "Liability Amount",
              "value": "As of December 31, 2022, the acquisition-related contingent consideration liability was $221.0 million."
            },
            {
              "key": "Audit Complexity",
              "value": "Auditing the valuation was complex and highly judgmental due to significant estimation required in determining fair value."
            },
            {
              "key": "Sensitivity Factors",
              "value": "The fair value estimate was sensitive to significant assumptions such as the discount rate and projected future net revenues of ICLUSIG."
            },
            {
              "key": "Future Expectations",
              "value": "These assumptions are affected by future industry, market and economic conditions, which are inherently uncertain."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 83,
          "title": "Acquisition-related contingent consideration liability",
          "data": [
            {
              "key": "audit procedures",
              "value": "To test the estimated fair value of the acquisition-related contingent consideration liability, we performed audit procedures that included assessing the terms of the arrangement and evaluating the methodology used."
            },
            {
              "key": "valuation specialists",
              "value": "Involved valuation specialists to assist in the evaluation of the significant assumptions and methodology."
            },
            {
              "key": "comparison",
              "value": "Compared significant assumptions to current industry, market, and economic trends and to the Company’s budgets and forecasts."
            },
            {
              "key": "historical accuracy",
              "value": "Assessed the historical accuracy of management’s estimates against actual performance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 93,
          "title": "Revenues and Accruals Regarding Commercial Insurance",
          "data": [
            {
              "key": "general_information",
              "value": "Commercial insurance rebates are based on data received from customers."
            },
            {
              "key": "accounting_method",
              "value": "Rebates are invoiced and paid in arrears."
            },
            {
              "key": "adjustment_impact",
              "value": "If actual future rebates vary from estimates, prior period accruals need adjustments affecting revenue."
            },
            {
              "key": "chargebacks",
              "value": "Chargebacks are discounts for contracted customers that primarily consist of certain organizations and entities."
            },
            {
              "key": "medicare_part_d",
              "value": "Manufacturers must fund 70% of the Medicare Part D coverage gap for prescription drugs."
            },
            {
              "key": "co_payment_assistance",
              "value": "Patients with commercial insurance may receive co-payment assistance."
            },
            {
              "key": "product_royalty_revenues",
              "value": "Royalty revenues are based on commercial sales of licensed products."
            },
            {
              "key": "milestone_revenue",
              "value": "Revenues from milestone payments under collaborative research agreements are estimated at the contract outset."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 100,
          "title": "Acquisition of Villaris Therapeutics, Inc.",
          "data": [
            {
              "key": "Date of Acquisition",
              "value": "November 17, 2022"
            },
            {
              "key": "Acquisition Details",
              "value": "100% of the outstanding shares of Villaris Therapeutics, Inc."
            },
            {
              "key": "Nature of Business",
              "value": "Early-stage biopharma company focused on novel antibody therapeutics for vitiligo"
            },
            {
              "key": "Purchase Price",
              "value": "$70.3 million"
            },
            {
              "key": "Asset Type",
              "value": "Preclinical asset"
            },
            {
              "key": "Transaction Type",
              "value": "Asset acquisition"
            },
            {
              "key": "Expected Milestone Payments",
              "value": "Up to $310 million for development and regulatory milestones; additional up to $1.05 billion in commercial milestones"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 101,
          "title": "License Agreements with Novartis",
          "data": [
            {
              "key": "Agreement Date",
              "value": "November 2009"
            },
            {
              "key": "Collaboration Rights",
              "value": "Exclusive development and commercialization rights outside of the US for JAK inhibitor ruxolitinib."
            },
            {
              "key": "Financial Milestones",
              "value": "Up to $174.0 million for development milestones, $495.0 million for regulatory milestones, and $500.0 million for sales milestones."
            },
            {
              "key": "Received Milestones",
              "value": "$157.0 million for development, $340.0 million for regulatory, and $200.0 million for sales milestones through December 31, 2022."
            },
            {
              "key": "Royalty Rate",
              "value": "Tiered royalties ranging from upper-teens to mid-twenties on future JAKAVI net sales outside of the US."
            },
            {
              "key": "Accrued Royalties",
              "value": "$253.5 million as of December 31, 2022, and $148.1 million as of December 31, 2021."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 105,
          "title": "Collaboration and License Agreement with Calithera Biosciences, Inc.",
          "data": [
            {
              "key": "Collaboration Date",
              "value": "January 2017"
            },
            {
              "key": "License Type",
              "value": "Worldwide"
            },
            {
              "key": "Licensed Products",
              "value": "small molecule arginase inhibitors, including INCB01158"
            },
            {
              "key": "Co-funding Obligation End Date",
              "value": "September 30, 2020"
            },
            {
              "key": "Termination Date",
              "value": "December 2022"
            },
            {
              "key": "Stock Purchase Agreement Purchase Date",
              "value": "2017"
            },
            {
              "key": "Total Shares Purchased",
              "value": "1.7 million shares"
            },
            {
              "key": "Purchase Price",
              "value": "$8.0 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 107,
          "title": "Collaboration and License Agreement with Syndax",
          "data": [
            {
              "key": "Collaboration Partner",
              "value": "Syndax Pharmaceuticals, Inc."
            },
            {
              "key": "Product Name",
              "value": "SNDX-6352 (axatilimab)"
            },
            {
              "key": "Incyte's Responsibility Share",
              "value": "55%"
            },
            {
              "key": "Syndax's Responsibility Share",
              "value": "45%"
            },
            {
              "key": "Upfront Payment to MorphoSys",
              "value": "$750.0 million"
            },
            {
              "key": "Future Milestones for MorphoSys",
              "value": "up to $737.5 million + $315.0 million in commercialization milestones"
            },
            {
              "key": "Investment Details",
              "value": "Purchased ADSs for $150.0 million"
            },
            {
              "key": "Investment Fair Market Value (2022)",
              "value": "$13.0 million"
            },
            {
              "key": "Investment Fair Market Value (2021)",
              "value": "$34.2 million"
            },
            {
              "key": "Research and Development Expenses 2022",
              "value": "$99.7 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 119,
          "title": "Net Periodic Benefit Cost and Pension Liability",
          "data": [
            {
              "key": "Service Cost 2022",
              "value": "9,855"
            },
            {
              "key": "Service Cost 2021",
              "value": "7,977"
            },
            {
              "key": "Service Cost 2020",
              "value": "6,047"
            },
            {
              "key": "Interest cost 2022",
              "value": "251"
            },
            {
              "key": "Interest cost 2021",
              "value": "92"
            },
            {
              "key": "Interest cost 2020",
              "value": "193"
            },
            {
              "key": "Expected return on plan 2022",
              "value": "(4,184)"
            },
            {
              "key": "Expected return on plan 2021",
              "value": "(60)"
            },
            {
              "key": "Expected return on plan 2020",
              "value": "(126)"
            },
            {
              "key": "Amortization of prior service cost 2022",
              "value": "773"
            },
            {
              "key": "Amortization of prior service cost 2021",
              "value": "217"
            },
            {
              "key": "Amortization of prior service cost 2020",
              "value": "216"
            },
            {
              "key": "Amortization of actuarial losses 2022",
              "value": "356"
            },
            {
              "key": "Amortization of actuarial losses 2021",
              "value": "1,154"
            },
            {
              "key": "Amortization of actuarial losses 2020",
              "value": "667"
            },
            {
              "key": "Net periodic benefit cost 2022",
              "value": "7,051"
            },
            {
              "key": "Net periodic benefit cost 2021",
              "value": "9,380"
            },
            {
              "key": "Net periodic benefit cost 2020",
              "value": "6,997"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 119,
          "title": "Pension Liability Statement",
          "data": [
            {
              "key": "Pension liability, beginning of year 2022",
              "value": "23,677"
            },
            {
              "key": "Plan amendment 2022",
              "value": ""
            },
            {
              "key": "Net prior service costs 2022",
              "value": "(773)"
            },
            {
              "key": "Net (gain) loss 2022",
              "value": "(24,603)"
            },
            {
              "key": "Pension (asset) liability, end of year 2022",
              "value": "(1,699)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 119,
          "title": "Expected Payments",
          "data": [
            {
              "key": "Payment for 2024",
              "value": "5,514"
            },
            {
              "key": "Payment for 2025",
              "value": "6,259"
            },
            {
              "key": "Payment for 2026",
              "value": "5,995"
            },
            {
              "key": "Payment for 2027",
              "value": "6,696"
            },
            {
              "key": "Payment for 2028",
              "value": "42,436"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 127,
          "title": "Exhibit Number Description of Document",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "101.SCH*"
            },
            {
              "key": "Description of Document",
              "value": "XBRL Taxonomy Extension Schema Document"
            },
            {
              "key": "Exhibit Number",
              "value": "101.CAL*"
            },
            {
              "key": "Description of Document",
              "value": "XBRL Taxonomy Extension Calculation Linkbase Document"
            },
            {
              "key": "Exhibit Number",
              "value": "101.LAB*"
            },
            {
              "key": "Description of Document",
              "value": "XBRL Taxonomy Extension Label Linkbase Document"
            },
            {
              "key": "Exhibit Number",
              "value": "101.PRE*"
            },
            {
              "key": "Description of Document",
              "value": "XBRL Taxonomy Presentation Linkbase Document"
            },
            {
              "key": "Exhibit Number",
              "value": "101.DEF*"
            },
            {
              "key": "Description of Document",
              "value": "XBRL Taxonomy Definition Linkbase Document"
            },
            {
              "key": "Description",
              "value": "Cover Page Interactive Data File (embedded within the Inline XBRL document)."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 65,
          "title": "Executive Officers Information",
          "data": [
            {
              "key": "CEO Name",
              "value": "Hervé Hoppenot"
            },
            {
              "key": "CEO Age",
              "value": "63"
            },
            {
              "key": "CEO Start Date",
              "value": "January 2014"
            },
            {
              "key": "Chairman Start Date",
              "value": "May 2015"
            },
            {
              "key": "Previous Position",
              "value": "President of Novartis Oncology"
            },
            {
              "key": "Executive VP Name",
              "value": "Dashyant Dhanak"
            },
            {
              "key": "Executive VP Age",
              "value": "62"
            },
            {
              "key": "Executive VP Start Date",
              "value": "December 2018"
            },
            {
              "key": "Previous Position",
              "value": "Vice President, Head of Discovery Sciences at Janssen Research & Development"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 66,
          "title": "Current Leadership Team at Incyte",
          "data": [
            {
              "key": "Jonathan E. Dickinson",
              "value": "Executive Vice President and General Manager, Europe (age 55) - joined Incyte in June 2016"
            },
            {
              "key": "Barry P. Flannelly",
              "value": "Executive Vice President and General Manager, North America (age 65) - joined Incyte in August 2014"
            },
            {
              "key": "Vijay Iyengar",
              "value": "Executive Vice President, Global Strategy and Corporate Development (age 50) - joined Incyte in May 2016"
            },
            {
              "key": "Michael Morrissey",
              "value": "Executive Vice President and Head of Global Technical Operations (age 59) - joined Incyte in January 2016"
            },
            {
              "key": "Maria E. Pasquale",
              "value": "Executive Vice President and General Counsel (age 57) - joined Incyte in April 2018"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 67,
          "title": "Leadership Changes at Incyte",
          "data": [
            {
              "key": "Christiana Stamoulis",
              "value": "Executive Vice President and Chief Financial Officer"
            },
            {
              "key": "Age",
              "value": "52"
            },
            {
              "key": "Joined Incyte",
              "value": "February 2019"
            },
            {
              "key": "Previous Position",
              "value": "President and Chief Financial Officer at Unum Therapeutics Inc."
            },
            {
              "key": "Steven Stein",
              "value": "Executive Vice President and Chief Medical Officer"
            },
            {
              "key": "Age",
              "value": "56"
            },
            {
              "key": "Joined Incyte",
              "value": "March 2015"
            },
            {
              "key": "Previous Position",
              "value": "Senior Vice President, US Clinical Development & Medical Affairs at Novartis Pharmaceuticals"
            },
            {
              "key": "Paula J. Swain",
              "value": "Executive Vice President, Human Resources"
            },
            {
              "key": "Age",
              "value": "65"
            },
            {
              "key": "Joined Incyte",
              "value": "January 2002"
            },
            {
              "key": "Previous Position",
              "value": "Senior Vice President of Human Resources at Bristol-Myers Squibb Company"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 123,
          "title": "Directors, Executive Officers and Corporate Governance",
          "data": [
            {
              "key": "Proxy Statement Filing Date",
              "value": "June 14, 2023"
            },
            {
              "key": "CEO",
              "value": "Not explicitly mentioned"
            },
            {
              "key": "CFO",
              "value": "Not explicitly mentioned"
            },
            {
              "key": "Principal Accounting Officer",
              "value": "Not explicitly mentioned"
            },
            {
              "key": "Corporate Controller",
              "value": "Not explicitly mentioned"
            },
            {
              "key": "Audit and Finance Committee Members",
              "value": "Mr. Paul J. Clancy, Dr. Jacqualyn A. Fouse, Dr. Edmund P. Harrigan"
            },
            {
              "key": "Audit Committee Financial Experts",
              "value": "Mr. Paul J. Clancy, Dr. Jacqualyn A. Fouse"
            },
            {
              "key": "Independent Directors",
              "value": "All members of the Audit Committee"
            },
            {
              "key": "Code of Business Conduct and Ethics",
              "value": "Adopted and applies to all officers and employees"
            },
            {
              "key": "Senior Financial Officers’ Code of Ethics",
              "value": "Adopted and applies to specific financial officers"
            },
            {
              "key": "Request for Code of Ethics",
              "value": "Contact: Investor Relations, Incyte Corporation"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 128,
          "title": "Document Signatures and Corporate Officers",
          "data": [
            {
              "key": "Signature",
              "value": "/s/ HERVE HOPPENOT Hervé Hoppenot"
            },
            {
              "key": "Title",
              "value": "Chairman, President, and Chief Executive Officer (Principal Executive Officer) and Director"
            },
            {
              "key": "Date",
              "value": "February 7, 2023"
            },
            {
              "key": "Signature",
              "value": "Christiana Stamoulis"
            },
            {
              "key": "Title",
              "value": "Chief Financial Officer (Principal Financial Officer)"
            },
            {
              "key": "Date",
              "value": "February 7, 2023"
            },
            {
              "key": "Signature",
              "value": "Thomas Tray"
            },
            {
              "key": "Title",
              "value": "VP, Chief Accounting Officer (Principal Accounting Officer)"
            },
            {
              "key": "Date",
              "value": "February 7, 2023"
            },
            {
              "key": "Signature",
              "value": "Julian C. Baker"
            },
            {
              "key": "Title",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "February 7, 2023"
            },
            {
              "key": "Signature",
              "value": "Jean-Jacques Bienaimé"
            },
            {
              "key": "Title",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "February 7, 2023"
            },
            {
              "key": "Signature",
              "value": "Otis W. Brawley"
            },
            {
              "key": "Title",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "February 7, 2023"
            },
            {
              "key": "Signature",
              "value": "Paul J. Clancy"
            },
            {
              "key": "Title",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "February 7, 2023"
            },
            {
              "key": "Signature",
              "value": "Jacqualyn A. Fouse"
            },
            {
              "key": "Title",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "February 7, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 129,
          "title": "Signature Block",
          "data": [
            {
              "key": "Name",
              "value": "Edmund P. Harrigan"
            },
            {
              "key": "Position",
              "value": "Direct Director"
            },
            {
              "key": "Date",
              "value": "February 7, 2023"
            },
            {
              "key": "Name",
              "value": "Katherine A. High"
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "February 7, 2023"
            },
            {
              "key": "Name",
              "value": "Susanne Schaffert"
            },
            {
              "key": "Position",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "February 7, 2023"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": false,
      "elements": []
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 9,
          "title": "JAKAFI Overview and Clinical Data",
          "data": [
            {
              "key": "FDA Approval Date",
              "value": "August 2014"
            },
            {
              "key": "Survival Rate COMFORT-I (3 Years)",
              "value": "70%"
            },
            {
              "key": "Survival Rate Placebo COMFORT-I (3 Years)",
              "value": "61%"
            },
            {
              "key": "Survival Rate COMFORT-II (3 Years)",
              "value": "79%"
            },
            {
              "key": "Survival Rate Best Available Therapy COMFORT-II (3 Years)",
              "value": "59%"
            },
            {
              "key": "Fatigue Improvement Rate JAKAFI",
              "value": "35%"
            },
            {
              "key": "Fatigue Improvement Rate Placebo",
              "value": "14%"
            },
            {
              "key": "Key Adverse Reactions",
              "value": "Thrombocytopenia, Anemia, Bruising, Dizziness, Headache"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 12,
          "title": "Approval of PEMAZYRE and ICLUSIG",
          "data": [
            {
              "key": "Date of PEMAZYRE approval in Japan",
              "value": "March 2021"
            },
            {
              "key": "Purpose of PEMAZYRE approval in Japan",
              "value": "Treatment of patients with unresectable biliary tract cancer (BTC) with an FGFR2 fusion gene"
            },
            {
              "key": "Date of PEMAZYRE approval in Europe",
              "value": "March 2021"
            },
            {
              "key": "Purpose of PEMAZYRE approval in Europe",
              "value": "Treatment of adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement"
            },
            {
              "key": "Recommendation by NICE",
              "value": "July 2021"
            },
            {
              "key": "Indication for NICE’s guidance",
              "value": "Access to PEMAZYRE for patients with cholangiocarcinoma with an FGFR2 fusion or rearrangement"
            },
            {
              "key": "Estimation of patients with cholangiocarcinoma and FGFR2 fusions",
              "value": "2,000-3,000 patients in the United States, Europe, and Japan"
            },
            {
              "key": "Primary endpoint of FIGHT-202",
              "value": "Overall response rate of 36%"
            },
            {
              "key": "Secondary endpoint of FIGHT-202",
              "value": "Median DOR of 9.1 months"
            },
            {
              "key": "Date of approval by NMPA in China",
              "value": "March 2022"
            },
            {
              "key": "Approval for MLNs by FDA",
              "value": "August 2022"
            },
            {
              "key": "Acquisition of ARIAD Pharmaceuticals",
              "value": "June 2016"
            },
            {
              "key": "LICUSIG indication for treatment",
              "value": "Treatment of adult patients with chronic phase, accelerated phase, or blast phase CML"
            },
            {
              "key": "Ruxolitinib program",
              "value": "LIMBER (Leadership In MPNs BEyond Ruxolitinib)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 73,
          "title": "Stock Compensation",
          "data": [
            {
              "key": "Share-based payment transactions",
              "value": "involve stock options, RSUs, and PSUs recognized as compensation expense"
            },
            {
              "key": "Valuation assumptions",
              "value": "Volatility: 36% (2022), 39% (2021); Expected option life: ~5 years; Annualized forfeiture rate: 5%"
            },
            {
              "key": "Risk-free interest rates",
              "value": "Increased from 0.62% (2021) to 2.14% (2022)"
            },
            {
              "key": "Expense recognition methods",
              "value": "Accelerated attribution for graded vesting, Straight-line for cliff vesting"
            },
            {
              "key": "Performance conditions",
              "value": "Assessed probability of achievement for PSUs based on product revenues and milestones"
            },
            {
              "key": "Monte Carlo simulation",
              "value": "Used for market performance conditions for PSUs"
            },
            {
              "key": "Deferred tax assets",
              "value": "Assessed likelihood of realization based on cumulative earnings, future projections, and tax strategies"
            },
            {
              "key": "Tax benefit recognition",
              "value": "Only if more-likely-than-not that the uncertain tax position will be sustained"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 87,
          "title": "Statement of Stockholders' Equity",
          "data": [
            {
              "key": "Balances at December 31,2019",
              "value": "Common Stock: 216, Additional Paid in Capital: 4044490, Other Comprehensive Income: -15542, Accumulated Deficit: -1430758, Total Stockholders Equity: 2598406"
            },
            {
              "key": "ESPP shares issuance",
              "value": "Common Stock: 3, Additional Paid in Capital: 110302, Total Stockholders Equity: 110305"
            },
            {
              "key": "Stock for services rendered",
              "value": "Additional Paid in Capital: 546, Total Stockholders Equity: 546"
            },
            {
              "key": "Convertible Senior Notes conversion",
              "value": "Additional Paid in Capital: 18999, Total Stockholders Equity: 18999"
            },
            {
              "key": "Stock compensation",
              "value": "Additional Paid in Capital: 178527, Total Stockholders Equity: 178527"
            },
            {
              "key": "Balances at December 31,2021",
              "value": "Common Stock: 221, Additional Paid in Capital: 4567111, Other Comprehensive Income: -19454, Accumulated Deficit: -777874, Total Stockholders Equity: 3770004"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 95,
          "title": "Stock Compensation",
          "data": [
            {
              "key": "Cost of Product Revenues",
              "value": "Cost of product revenues includes all product related costs, royalties owed under collaboration and license agreements."
            },
            {
              "key": "Stock Compensation Overview",
              "value": "Share-based payment transactions with employees, including stock options, RSUs, and PSUs are recognized as compensation expense."
            },
            {
              "key": "Method of Recognition",
              "value": "The fair value of stock options is recognized over the requisite service period using the accelerated attribution method."
            },
            {
              "key": "Judgment in Estimation",
              "value": "Significant judgment is required, particularly with Black-Scholes assumptions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 96,
          "title": "Compensation Expense Recognition and Long Term Incentive Plans",
          "data": [
            {
              "key": "RSUs Expensed",
              "value": "Recognized as compensation expense over the requisite service period using accelerated attribution."
            },
            {
              "key": "PSUs Expensed",
              "value": "Recognized as compensation expense beginning when performance conditions are probable."
            },
            {
              "key": "Advertising Expenses",
              "value": "$196.4 million for 2022, $66.0 million for 2021, $28.9 million for 2020."
            },
            {
              "key": "Long Term Incentive Plans",
              "value": "Provide eligible employees with performance and service-based incentive compensation."
            },
            {
              "key": "Acquisition-Related Contingent Consideration",
              "value": "Future royalty obligations owed to Takeda Pharmaceutical from acquisition of ARIAD."
            },
            {
              "key": "Transaction Accounting Judgments",
              "value": "Includes determining if acquired assets meet business definition under accounting rules."
            },
            {
              "key": "Goodwill Treatment",
              "value": "Excess of purchase price over fair value of acquired net assets recorded as goodwill."
            },
            {
              "key": "Asset Acquisition Accounting",
              "value": "Purchase price allocated to acquired asset without recording goodwill."
            },
            {
              "key": "In-Process R&D Treatment",
              "value": "Charged to expense at acquisition date if no alternative future use."
            },
            {
              "key": "Collaboration Agreement Share",
              "value": "50% share of United States loss for MONJUVI commercialization for 2022 and 2021."
            },
            {
              "key": "Recent Accounting Pronouncements",
              "value": "No new pronouncements affecting financial position or operations by year-end 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 99,
          "title": "Fair Value Measurements of Liabilities",
          "data": [
            {
              "key": "Description",
              "value": "Acquisition-related contingent consideration"
            },
            {
              "key": "Level 1",
              "value": "$0"
            },
            {
              "key": "Level 2",
              "value": "$0"
            },
            {
              "key": "Level 3",
              "value": "$244,000"
            },
            {
              "key": "Total Balance",
              "value": "$244,000"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 99,
          "title": "Contingent Consideration Balance Reconciliation",
          "data": [
            {
              "key": "description",
              "value": "Balance at January 1"
            },
            {
              "key": "2022",
              "value": "$244,000"
            },
            {
              "key": "2021",
              "value": "$266,000"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 103,
          "title": "Lilly Agreement Financial Terms",
          "data": [
            {
              "key": "milestone_revenue_2022",
              "value": "$70.0 million"
            },
            {
              "key": "milestone_revenue_2021",
              "value": "$50.0 million"
            },
            {
              "key": "milestone_revenue_2020",
              "value": "$30.0 million"
            },
            {
              "key": "product_royalty_revenues_2022",
              "value": "$134.5 million"
            },
            {
              "key": "product_royalty_revenues_2021",
              "value": "$220.9 million"
            },
            {
              "key": "product_royalty_revenues_2020",
              "value": "$110.9 million"
            },
            {
              "key": "regulatory_milestones_payments",
              "value": "up to $40.0 million"
            },
            {
              "key": "triggered_payment_1",
              "value": "$20.0 million for JAKAFI approval"
            },
            {
              "key": "triggered_payment_2",
              "value": "$20.0 million for EMA recommendation"
            },
            {
              "key": "Agenus_milestones_paid",
              "value": "$30.0 million"
            },
            {
              "key": "Agenus_future_milestones",
              "value": "up to $500.0 million"
            },
            {
              "key": "shares_purchased_Agenus",
              "value": "10.0 million shares for $60.0 million"
            },
            {
              "key": "gross_proceeds_sale_Agenus_2020",
              "value": "$17.2 million"
            },
            {
              "key": "gross_proceeds_sale_Agenus_2021",
              "value": "$10.5 million"
            },
            {
              "key": "fair_market_value_Agenus_2022",
              "value": "$29.0 million"
            },
            {
              "key": "fair_market_value_Agenus_2021",
              "value": "$38.9 million"
            },
            {
              "key": "unrealized_loss_2022",
              "value": "$9.9 million"
            },
            {
              "key": "unrealized_gain_2021",
              "value": "$4.6 million"
            },
            {
              "key": "unrealized_loss_2020",
              "value": "$10.3 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 104,
          "title": "Merus Agreement and Financial Overview",
          "data": [
            {
              "key": "collaboration_scope",
              "value": "Collaboration with Merus for bispecific antibody development, encompassing up to ten independent programs."
            },
            {
              "key": "MCLA-145_status",
              "value": "Opted-out of continued development of MCLA-145 targeting PD-L1 and CD137."
            },
            {
              "key": "development_costs",
              "value": "Merus will co-fund development of up to two programs, responsible for 35% of global costs and reimburse certain prior costs."
            },
            {
              "key": "milestone_payments",
              "value": "Eligible for up to $100 million in development milestones and $250 million in commercialization milestones."
            },
            {
              "key": "royalties",
              "value": "Tiered royalties of 6% to 10% on global net sales for each program."
            },
            {
              "key": "additional_royalties",
              "value": "Additional royalties up to 4% if Merus ceases co-funding."
            },
            {
              "key": "payments_to_merus",
              "value": "Paid Merus $3.0 million in milestones, recorded as R&D expense."
            },
            {
              "key": "share_subscription",
              "value": "Entered into a Share Subscription Agreement purchasing 3.2 million shares for $80.0 million."
            },
            {
              "key": "current_ownership",
              "value": "Owned 8% of Merus common shares as of December 31, 2022."
            },
            {
              "key": "fair_value_investment",
              "value": "Total long term investment valued at $54.9 million as of December 31, 2022."
            },
            {
              "key": "unrealized_gains_losses",
              "value": "Recorded unrealized loss of $58.0 million in 2022, gain of $48.1 million in 2021, gain of $11.0 million in 2020."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 112,
          "title": "Share Options Summary",
          "data": [
            {
              "key": "date",
              "value": "December 31, 2021"
            },
            {
              "key": "shares",
              "value": "12763460"
            },
            {
              "key": "weighted_average_exercise_price",
              "value": "88.39"
            },
            {
              "key": "description",
              "value": "Options granted"
            },
            {
              "key": "shares",
              "value": "1856979"
            },
            {
              "key": "weighted_average_exercise_price",
              "value": "75.26"
            },
            {
              "key": "description",
              "value": "Options exercised"
            },
            {
              "key": "shares",
              "value": "-631354"
            },
            {
              "key": "weighted_average_exercise_price",
              "value": "68.04"
            },
            {
              "key": "description",
              "value": "Options cancelled"
            },
            {
              "key": "shares",
              "value": "-1338726"
            },
            {
              "key": "weighted_average_exercise_price",
              "value": "90.55"
            },
            {
              "key": "date",
              "value": "December 31, 2022"
            },
            {
              "key": "shares",
              "value": "12650359"
            },
            {
              "key": "weighted_average_exercise_price",
              "value": "87.25"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 113,
          "title": "Outstanding Awards",
          "data": [
            {
              "key": "Balance at December",
              "value": "3966888 shares (grant date value: $84.91)"
            },
            {
              "key": "RSUs granted",
              "value": "2527740 shares (grant date value: $77.08)"
            },
            {
              "key": "PSUs granted 2",
              "value": "154685 shares (grant date value: $77.67)"
            },
            {
              "key": "RSUs released",
              "value": "-870509 shares (grant date value: $86.75)"
            },
            {
              "key": "PSUs released",
              "value": "-184401 shares (grant date value: $69.25)"
            },
            {
              "key": "RSUs cancelled",
              "value": "-405091 shares (grant date value: $83.51)"
            },
            {
              "key": "PSUs cancelled",
              "value": "-1720 shares (grant date value: $65.76)"
            },
            {
              "key": "Balance at December",
              "value": "5187592 shares (grant date value: $81.24)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 113,
          "title": "Available Shares Under the 2010 Plan",
          "data": [
            {
              "key": "",
              "value": "for Grant"
            },
            {
              "key": "Balance at December 31, 2021",
              "value": "10,113,298"
            },
            {
              "key": "Options, RSUs and PSUs granted...",
              "value": "(7,222,187)"
            },
            {
              "key": "Options, RSUs and PSUs cancelled",
              "value": "2,165,259"
            },
            {
              "key": "Balance at December 31, 2022",
              "value": "5,056,370"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 113,
          "title": "Employee Stock Purchase Plan",
          "data": [
            {
              "key": "Shares issued in 2022",
              "value": "308,413"
            },
            {
              "key": "Shares issued in 2021",
              "value": "264,503"
            },
            {
              "key": "Shares issued in 2020",
              "value": "258,453"
            },
            {
              "key": "Stock compensation expense 2022",
              "value": "$4.7 million"
            },
            {
              "key": "Stock compensation expense 2021",
              "value": "$4.6 million"
            },
            {
              "key": "Stock compensation expense 2020",
              "value": "$4.6 million"
            },
            {
              "key": "Shares available for issuance under ESPP as of Dec 31, 2022",
              "value": "372,562"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 114,
          "title": "Financial Metrics Analysis for Years 2020-2022",
          "data": [
            {
              "key": "Average risk-free interest rates 2022",
              "value": "2.14%"
            },
            {
              "key": "Average risk-free interest rates 2021",
              "value": "0.62%"
            },
            {
              "key": "Average risk-free interest rates 2020",
              "value": "0.80%"
            },
            {
              "key": "Average expected life (in years) 2022",
              "value": "4.90"
            },
            {
              "key": "Average expected life (in years) 2021",
              "value": "5.01"
            },
            {
              "key": "Average expected life (in years) 2020",
              "value": "4.98"
            },
            {
              "key": "Volatility 2022",
              "value": "36%"
            },
            {
              "key": "Volatility 2021",
              "value": "39%"
            },
            {
              "key": "Volatility 2020",
              "value": "40%"
            },
            {
              "key": "Weighted-average fair value 2022",
              "value": "26.06"
            },
            {
              "key": "Weighted-average fair value 2021",
              "value": "29.03"
            },
            {
              "key": "Weighted-average fair value 2020",
              "value": "32.65"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 118,
          "title": "Employee Benefit Plans",
          "data": [
            {
              "key": "Defined Contribution Expense 2022",
              "value": "$18.7 million"
            },
            {
              "key": "Defined Contribution Expense 2021",
              "value": "$16.7 million"
            },
            {
              "key": "Defined Contribution Expense 2020",
              "value": "$13.4 million"
            },
            {
              "key": "Benefit Obligation, 2022",
              "value": "$113,705"
            },
            {
              "key": "Benefit Obligation, 2021",
              "value": "$131,966"
            },
            {
              "key": "Unfunded Liability, end of 2022",
              "value": "$11,682"
            },
            {
              "key": "Unfunded Liability, end of 2021",
              "value": "$37,971"
            },
            {
              "key": "Employer Contributions to Pension Plans 2022",
              "value": "$7,617"
            },
            {
              "key": "Employer Contributions to Pension Plans 2021",
              "value": "$6,858"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 13,
          "title": "Overview of New Drug Applications and Ongoing Clinical Trials",
          "data": [
            {
              "key": "Drug Name",
              "value": "ruxolitinib"
            },
            {
              "key": "NDA Acceptance Date",
              "value": "March 23, 2023"
            },
            {
              "key": "PDUFA Action Date",
              "value": "March 23, 2023"
            },
            {
              "key": "Trial Names",
              "value": "LIMBER-313, LIMBER-304, AGAVE-201, L-MIND, B-MIND, firstMIND, frontMIND, inMIND"
            },
            {
              "key": "Collaboration Partner",
              "value": "Syndax Pharmaceuticals, Inc."
            },
            {
              "key": "Indication",
              "value": "chronic GVHD"
            },
            {
              "key": "Fast-Track Designation",
              "value": "Yes (axatilimab, May 2022)"
            },
            {
              "key": "Other Compounds",
              "value": "INCB57643 (BET), INCB00928 (ALK2), tafasitamab"
            },
            {
              "key": "FDA Orphan Drug Designation",
              "value": "January 2021 for tafasitamab"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 108,
          "title": "Research and Development Expenses Related to Syndax and CMS Aesthetics Limited",
          "data": [
            {
              "key": "Upfront Payment to Syndax",
              "value": "$117.0 million"
            },
            {
              "key": "Future Contingent Payments to Syndax",
              "value": "up to $220.0 million in development milestones; up to $230.0 million in sales milestones"
            },
            {
              "key": "Royalty Rates",
              "value": "mid-teens on net sales in Europe and Japan; low double digit on net sales outside the US"
            },
            {
              "key": "Shares of Syndax Purchased",
              "value": "1.4 million shares for $35.0 million"
            },
            {
              "key": "Fair Market Value of Investment in Syndax (2022)",
              "value": "$36.2 million"
            },
            {
              "key": "Fair Market Value of Investment in Syndax (2021)",
              "value": "$31.1 million"
            },
            {
              "key": "Unrealized Gain (2022)",
              "value": "$5.1 million"
            },
            {
              "key": "Unrealized Gain (2021)",
              "value": "$6.3 million"
            },
            {
              "key": "Upfront Payment to CMS",
              "value": "$30.0 million"
            },
            {
              "key": "Additional Potential Payments under CMS Agreement",
              "value": "Contingent on future events such as milestones and sales royalties"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 8,
          "title": "Incyte Business Overview and Product Line",
          "data": [
            {
              "key": "Company",
              "value": "Incyte"
            },
            {
              "key": "Focus",
              "value": "Discovery, development and commercialization of proprietary therapeutics"
            },
            {
              "key": "Headquarters",
              "value": "Wilmington, Delaware and other global locations"
            },
            {
              "key": "Therapeutic Areas",
              "value": "Hematology/Oncology and Inflammation and Autoimmunity"
            },
            {
              "key": "Key Products",
              "value": "JAKAFI, MONJUVI/MINJUVI, PEMAZYRE, ICLUSIG"
            },
            {
              "key": "JAKAFI Approval Dates",
              "value": "November 2011, December 2014, May 2019, September 2021"
            },
            {
              "key": "Collaboration Partner",
              "value": "Novartis Pharmaceutical International Ltd."
            },
            {
              "key": "JAK Inhibitors",
              "value": "JAK1 and JAK2 inhibitors for hematological malignancies and immune diseases"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 10,
          "title": "FDA Approval and Data for JAKAFI in Polycythemia Vera and Acute Graft-Versus-Host Disease",
          "data": [
            {
              "key": "Product Name",
              "value": "JAKAFI"
            },
            {
              "key": "Indications",
              "value": "Treatment of patients with polycythemia vera (PV), steroid-refractory acute graft-versus-host disease (GVHD)"
            },
            {
              "key": "Key Approvals",
              "value": "Approved for PV by FDA in December 2014; approved for steroid-refractory acute GVHD in May 2019; approved for chronic GVHD in September 2021"
            },
            {
              "key": "Clinical Trial Data",
              "value": "RESPONSE trial, RESPONSE-2 study, REACH1 study, REACH3 study"
            },
            {
              "key": "Patient Outcomes",
              "value": "Superior hematocrit control, overall response rate for GVHD of 57%, chronic GVHD overall response rate of 70% for JAKAFI"
            },
            {
              "key": "Adverse Reactions",
              "value": "Thrombocytopenia, anemia, infections, edema, neutropenia"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 11,
          "title": "Product Launch of MONJUVI and MINJUVI",
          "data": [
            {
              "key": "Product Name",
              "value": "MONJUVI (tafasitamab-cxix) / MINJUVI (tafasitamab)"
            },
            {
              "key": "Collaboration Partner",
              "value": "MorphoSys AG"
            },
            {
              "key": "FDA Approval Date",
              "value": "July 2020"
            },
            {
              "key": "Indication",
              "value": "Combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)."
            },
            {
              "key": "Response Rate",
              "value": "Objective response rate (ORR) of 55% for MONJUVI"
            },
            {
              "key": "Complete Response Rate",
              "value": "CR rate of 37% for MONJUVI"
            },
            {
              "key": "Median Duration of Response",
              "value": "21.7 months for MONJUVI"
            },
            {
              "key": "Side Effects",
              "value": "Infections (26%), pneumonia (7%), febrile neutropenia (6%)"
            },
            {
              "key": "European Commission Approval Date",
              "value": "August 2021"
            },
            {
              "key": "Marketing Authorization Granted For",
              "value": "MINJUVI (tafasitamab) in combination with lenalidomide"
            },
            {
              "key": "Best ORR for MINJUVI",
              "value": "56.8%"
            },
            {
              "key": "CR Rate for MINJUVI",
              "value": "39.5%"
            },
            {
              "key": "PR Rate for MINJUVI",
              "value": "17.3%"
            },
            {
              "key": "Median Duration of Response for MINJUVI",
              "value": "43.9 months after a minimum follow up of 35 months"
            },
            {
              "key": "Warnings and Precautions",
              "value": "Infusion-related reactions, myelosuppression, infections and tumour lysis syndrome."
            },
            {
              "key": "Global Estimated Patients with r/r DLBCL (US)",
              "value": "~10,000 patients"
            },
            {
              "key": "Global Estimated Patients with r/r DLBCL (EU)",
              "value": "~14,000 patients"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 15,
          "title": "Clinical Development Pipeline",
          "data": [
            {
              "key": "drug",
              "value": "ruxolitinib XR (QD) (JAKI/JAK2) ruxolitinib + parsaclisib (JAK1/JAK2 + PI3K8)"
            },
            {
              "key": "indication_and_status",
              "value": "Myelofibrosis, polycythemia vera and GVHD: NDA under review"
            },
            {
              "key": "indication_and_status",
              "value": "Myelofibrosis: Phase III (first-line therapy) (LIMBER-313)"
            },
            {
              "key": "indication_and_status",
              "value": "Myelofibrosis: Phase III (suboptimal responders to ruxolitinib) (LIMBER-304)"
            },
            {
              "key": "drug",
              "value": "ruxolitinib + INCB57643 (JAK1/JAK2 + BET)"
            },
            {
              "key": "indication_and_status",
              "value": "Myelofibrosis: Phase II"
            },
            {
              "key": "drug",
              "value": "ruxolitinib + zilurgisertib (JAK1/JAK2 + ALK2)"
            },
            {
              "key": "indication_and_status",
              "value": "Myelofibrosis: Phase II"
            },
            {
              "key": "drug",
              "value": "ruxolitinib + CK0804™ (JAK1/JAK2 + CB-Tregs)"
            },
            {
              "key": "indication_and_status",
              "value": "Myelofibrosis: Phase I (LIMBER-TREG108)"
            },
            {
              "key": "drug",
              "value": "ruxolitinib + axatilimab (JAK1/JAK2 + anti-CSF-1R)"
            },
            {
              "key": "indication_and_status",
              "value": "Chronic GVHD (newly diagnosed): Phase I/II in preparation"
            },
            {
              "key": "drug",
              "value": "axatilimab (anti-CSF-1R)®"
            },
            {
              "key": "indication_and_status",
              "value": "Chronic GVHD: Pivotal Phase II (third-line plus therapy) (AGAVE-201)"
            },
            {
              "key": "drug",
              "value": "tafasitamab (CD19)"
            },
            {
              "key": "indication_and_status",
              "value": "t/r DLBCL: Phase II (L-MIND); Phase III (B-MIND)"
            },
            {
              "key": "indication_and_status",
              "value": "1L DLBCL: Phase III (frontMIND)"
            },
            {
              "key": "indication_and_status",
              "value": "t/r follicular & marginal zone lymphomas: Phase III (inMIND)"
            },
            {
              "key": "drug",
              "value": "pemigatinib (FGFR1/2/3)"
            },
            {
              "key": "indication_and_status",
              "value": "Myeloid/lymphoid neoplasms (MLN): Phase II (FIGHT-203); approved by FDA"
            },
            {
              "key": "indication_and_status",
              "value": "CCA: Phase III (FIGHT-302)"
            },
            {
              "key": "indication_and_status",
              "value": "Glioblastoma: Phase II (FIGHT-209)"
            },
            {
              "key": "drug",
              "value": "parsaclisib (PI3KS) retifanlimab (PD-1)"
            },
            {
              "key": "indication_and_status",
              "value": "NSCLC: Phase II (FIGHT-210)"
            },
            {
              "key": "indication_and_status",
              "value": "Warm autoimmune hemolytic anemia: Phase II] (PATHWAY)"
            },
            {
              "key": "indication_and_status",
              "value": "SCAC: Phase III (PODIUM-303)"
            },
            {
              "key": "indication_and_status",
              "value": "MSI-high endometrial cancer: Phase II (PODIUM-101, PODIUM-204)"
            },
            {
              "key": "drug",
              "value": "Merkel cell carcinoma"
            },
            {
              "key": "indication_and_status",
              "value": "Phase II (POD1UM-201)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 16,
          "title": "Clinical Trials and Pharmaceutical Compound Portfolio",
          "data": [
            {
              "key": "vCB99318 (Oral PD-L1)",
              "value": "KRASG12C-mutated solid tumors: adagrasib, in preparation"
            },
            {
              "key": "Phase I/Ib in",
              "value": "Solid tumors: Phase I"
            },
            {
              "key": "Combination",
              "value": ""
            },
            {
              "key": "With",
              "value": ""
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 16,
          "title": "Modality Candidates",
          "data": [
            {
              "key": "Category",
              "value": "Small molecules"
            },
            {
              "key": "Compounds",
              "value": "INCB81776 (AXL/MER), INCB106385 (A2A/A2B), INCB123667 (CDK2)"
            },
            {
              "key": "Category",
              "value": "Bispecific antibodies"
            },
            {
              "key": "Compounds",
              "value": "INCA32459 (LAG-3xPD-1)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 17,
          "title": "OPZELURA Launches for Atopic Dermatitis and Vitiligo",
          "data": [
            {
              "key": "Product Name",
              "value": "OPZELURA (ruxolitinib) cream"
            },
            {
              "key": "FDA Approval Date for Atopic Dermatitis",
              "value": "September 2021"
            },
            {
              "key": "FDA Approval Date for Vitiligo",
              "value": "July 2022"
            },
            {
              "key": "Indications",
              "value": "Topical treatment for mild to moderate atopic dermatitis and nonsegmental vitiligo"
            },
            {
              "key": "Key Benefits for Atopic Dermatitis",
              "value": "Significantly more patients achieved IGA Treatment Success at Week 8 (53.8% in TRuE-AD1, 51.3% in TRuE-AD2) compared to vehicle (15.1%, 7.6%)"
            },
            {
              "key": "Key Benefits for Vitiligo",
              "value": "First and only FDA approved treatment for repigmentation of vitiligo lesions; 29.9% of patients achieving >75% improvement in F-VASI75 at Week 24"
            },
            {
              "key": "Common Adverse Reactions for Atopic Dermatitis",
              "value": "Nasopharyngitis, diarrhea, bronchitis, ear infection, eosinophil count increased, urticaria, folliculitis, tonsillitis, rhinorrhea"
            },
            {
              "key": "Common Adverse Reactions for Vitiligo",
              "value": "Application site acne, application site pruritus, nasopharyngitis, headache, urinary tract infection, application site erythema, pyrexia"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 19,
          "title": "Indication and status INCB00928 (ALK2) Fibrodysplasia ossificans progressiva: Phase II Collaborative Partnered Programs",
          "data": [
            {
              "key": "Product Name",
              "value": "baricitinib"
            },
            {
              "key": "Collaborative Partner",
              "value": "Eli Lilly and Company"
            },
            {
              "key": "Product Type",
              "value": "JAK1 and JAK2 inhibitor"
            },
            {
              "key": "Indication",
              "value": "Rheumatoid Arthritis"
            },
            {
              "key": "Approval Date (FDA)",
              "value": "January 2016"
            },
            {
              "key": "Marketing Approval (EMA)",
              "value": "February 2017"
            },
            {
              "key": "Marketing Approval (MHLW)",
              "value": "July 2017"
            },
            {
              "key": "FDA Approval (2mg dose)",
              "value": "June 2018"
            },
            {
              "key": "Phase III Trials",
              "value": "All trials met primary endpoints"
            },
            {
              "key": "Atopic Dermatitis Trials",
              "value": "Phase IIa trial and Phase III programs conducted with positive outcomes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 21,
          "title": "Capmatinib Overview",
          "data": [
            {
              "key": "Product Name",
              "value": "Capmatinib"
            },
            {
              "key": "Description",
              "value": "A potent and highly selective MET inhibitor evaluated in patients with various cancers."
            },
            {
              "key": "FDA Approval Date",
              "value": "May 2020"
            },
            {
              "key": "Trade Name",
              "value": "TABRECTA"
            },
            {
              "key": "Indications",
              "value": "Adult patients with metastatic NSCLC with MET exon 14 skipping."
            },
            {
              "key": "Response Rate",
              "value": "Confirmed overall response rate of 68% in METex14 population."
            },
            {
              "key": "Common AEs",
              "value": "Peripheral edema, nausea, fatigue, vomiting, dyspnea, decreased appetite."
            },
            {
              "key": "Collaboration Partner",
              "value": "Novartis"
            },
            {
              "key": "Study Publication",
              "value": "Results published in The New England Journal of Medicine."
            },
            {
              "key": "Regulatory Approvals",
              "value": "Approved by MHLW, EC for METex14 mutation-positive NSCLC."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 22,
          "title": "Baricitinib, Capmatinib, Ruxolitinib - Product Launch and Licensing Details",
          "data": [
            {
              "key": "Product Name",
              "value": "Baricitinib"
            },
            {
              "key": "Indications",
              "value": "Atopic dermatitis, Severe alopecia areata"
            },
            {
              "key": "Approval Status",
              "value": "Approved in Europe and Japan; Approved in the United States"
            },
            {
              "key": "Licensed to",
              "value": "Lilly"
            },
            {
              "key": "Product Name 2",
              "value": "Capmatinib"
            },
            {
              "key": "Indications 2",
              "value": "NSCLC with MET exon 14 skipping mutations"
            },
            {
              "key": "Approval Status 2",
              "value": "Approved in the United States, Europe and Japan"
            },
            {
              "key": "Licensed to 2",
              "value": "Novartis"
            },
            {
              "key": "Product Name 3",
              "value": "Ruxolitinib"
            },
            {
              "key": "Indications 3",
              "value": "Acute and chronic GVHD"
            },
            {
              "key": "Approval Status 3",
              "value": "Approved in Europe; J-NDA under review"
            },
            {
              "key": "Licensed to 3",
              "value": "Novartis ex-US"
            },
            {
              "key": "Collaboration with Novartis",
              "value": "Collaboration and License Agreement from November 2009"
            },
            {
              "key": "Collaboration with Lilly",
              "value": "License, Development and Commercialization Agreement from December 2009"
            },
            {
              "key": "Collaboration with Innovent",
              "value": "Research Collaboration and Licensing Agreement from December 2018"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 23,
          "title": "Collaboration and License Agreements",
          "data": [
            {
              "key": "InnoCare",
              "value": "Collaboration and License Agreement entered in August 2021 for tafasitamab in hematology and oncology."
            },
            {
              "key": "Maruho",
              "value": "Strategic Alliance Agreement entered in April 2022 for ruxolitinib cream in autoimmune diseases in Japan."
            },
            {
              "key": "CMS Aesthetics",
              "value": "Collaboration and License Agreement in December 2022 for ruxolitinib cream in autoimmune diseases in multiple regions."
            },
            {
              "key": "Agenus",
              "value": "License, Development and Commercialization Agreement in January 2015 for novel immuno-therapeutics."
            },
            {
              "key": "Merus",
              "value": "Collaboration and License Agreement in December 2016 for bispecific antibodies."
            },
            {
              "key": "MacroGenics",
              "value": "Global Collaboration and License Agreement in October 2017 for investigational monoclonal antibody INCMGA0012."
            },
            {
              "key": "Syros",
              "value": "Target Discovery and Research Collaboration Agreement in January 2018 utilizing proprietary gene control platform."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 24,
          "title": "Collaboration and License Agreements",
          "data": [
            {
              "key": "Focus Area",
              "value": "myeloproliferative neoplasms"
            },
            {
              "key": "Collaborators",
              "value": "MorphoSys AG, Syndax"
            },
            {
              "key": "Product Names",
              "value": "MOR208 (tafasitamab), SNDX-6352 (axatilimab)"
            },
            {
              "key": "Collaboration Rights",
              "value": "Exclusive commercialization rights outside the US"
            },
            {
              "key": "Co-commercialization Rights",
              "value": "MorphoSys and Syndax in the US"
            },
            {
              "key": "FDA Designation",
              "value": "Orphan Drug Designation for SNDX-6352"
            },
            {
              "key": "Drug Discovery Approach",
              "value": "Integrated medicinal chemistry, biologists, pharmaceutical scientists"
            },
            {
              "key": "Novel Therapeutic Target Discovery",
              "value": "Up to seven validated targets"
            },
            {
              "key": "Therapeutics Focus",
              "value": "Targeted oncology"
            },
            {
              "key": "Development Objective",
              "value": "Rapid progression of lead candidates to clinical trials"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 25,
          "title": "Product Launches and Patent Status",
          "data": [
            {
              "key": "Drug/Drug Candidate (Target)",
              "value": "uxolitinib (JAK)"
            },
            {
              "key": "Status of U.S. Composition of Matter Patent Estate",
              "value": "Granted and pending (2028)"
            },
            {
              "key": "Status of EU Composition of Matter Patent Estate",
              "value": "Granted and pending (2027)"
            },
            {
              "key": "Status of Japan Composition Matter Patent Estate",
              "value": "Granted and pending (2028)"
            },
            {
              "key": "Drug/Drug Candidate (Target)",
              "value": "yaricitinib (JAK)"
            },
            {
              "key": "Status of U.S. Composition of Matter Patent Estate",
              "value": "Granted and pending (2030)"
            },
            {
              "key": "Status of EU Composition of Matter Patent Estate",
              "value": "Granted and pending (2032)"
            },
            {
              "key": "Status of Japan Composition Matter Patent Estate",
              "value": "Granted and pending (2033)"
            },
            {
              "key": "Drug/Drug Candidate (Target)",
              "value": "tacitinib (JAK)"
            },
            {
              "key": "Status of U.S. Composition of Matter Patent Estate",
              "value": "Granted and pending (2032)"
            },
            {
              "key": "Status of EU Composition of Matter Patent Estate",
              "value": "Granted and pending (2031)"
            },
            {
              "key": "Status of Japan Composition Matter Patent Estate",
              "value": "Granted and pending (2031)"
            },
            {
              "key": "Drug/Drug Candidate (Target)",
              "value": "apmatinib (MET)"
            },
            {
              "key": "Status of U.S. Composition of Matter Patent Estate",
              "value": "Granted and pending (2027)"
            },
            {
              "key": "Status of EU Composition of Matter Patent Estate",
              "value": "Granted and pending (2027)"
            },
            {
              "key": "Status of Japan Composition Matter Patent Estate",
              "value": "Granted and pending (2032)"
            },
            {
              "key": "Drug/Drug Candidate (Target)",
              "value": "parsaclisib (PI3Kδ)"
            },
            {
              "key": "Status of U.S. Composition of Matter Patent Estate",
              "value": "Granted and pending (2033)"
            },
            {
              "key": "Status of EU Composition of Matter Patent Estate",
              "value": "Granted and pending (2032)"
            },
            {
              "key": "Status of Japan Composition Matter Patent Estate",
              "value": "Granted and pending (2032)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 46,
          "title": "Product Development and Commercialization Challenges",
          "data": [
            {
              "key": "Potential Risks in Drug Development",
              "value": "We may be unsuccessful in our efforts to discover and develop drug candidates and commercialize drug products."
            },
            {
              "key": "Dependencies for Success",
              "value": "Our long term success, revenue growth and diversification of revenues depends on our ability to obtain regulatory approval for new drug products."
            },
            {
              "key": "Challenges in Drug Discovery",
              "value": "Discovery and development of drug candidates are expensive, uncertain and time-consuming."
            },
            {
              "key": "Current Development Stage",
              "value": "We have a number of drug candidates in Phase III clinical trials."
            },
            {
              "key": "Historical Example of Discontinuation",
              "value": "In April 2018, we along with Merck stopped the ECHO-301 study with epacadostat."
            },
            {
              "key": "Financial Impact on Operations",
              "value": "Unsuccessful product approval may adversely affect our operating results and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 69,
          "title": "Regulatory Achievements",
          "data": [
            {
              "key": "JAKAVI Approval",
              "value": "Approved for treatment of chronic GVHD (May 2022)"
            },
            {
              "key": "OLUMIANT Approval (COVID-19)",
              "value": "Approved for hospitalized adults requiring oxygen support (May 2022)"
            },
            {
              "key": "TABRECTA Approval",
              "value": "Approved as monotherapy for advanced non-small cell lung cancer (June 2022)"
            },
            {
              "key": "OLUMIANT Approval (Alopecia Areata)",
              "value": "First treatment approved for severe alopecia areata (June 2022)"
            },
            {
              "key": "OPZELURA Approval",
              "value": "First treatment for vitiligo in adults and pediatrics (July 2022)"
            },
            {
              "key": "PEMAZYRE Approval",
              "value": "First treatment for myeloid/lymphoid neoplasms with FGFR1 rearrangement (August 2022)"
            },
            {
              "key": "JAKAFI Labelling Update",
              "value": "Updated Pediatric Use section in prescribing information (December 2022)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 75,
          "title": "Year Ended December 31, 2022 - Allowances and Rebates Movement",
          "data": [
            {
              "key": "Period",
              "value": "Balance at January 1, 2022"
            },
            {
              "key": "Discounts and Distribution Fees",
              "value": "14678"
            },
            {
              "key": "Government Rebates and Chargebacks",
              "value": "99304"
            },
            {
              "key": "Assistance and Other Discounts",
              "value": "24074"
            },
            {
              "key": "Product Returns",
              "value": "4740"
            },
            {
              "key": "Total",
              "value": "142796"
            },
            {
              "key": "Period",
              "value": "Allowances for current period sales"
            },
            {
              "key": "Discounts and Distribution Fees",
              "value": "119977"
            },
            {
              "key": "Government Rebates and Chargebacks",
              "value": "621051"
            },
            {
              "key": "Assistance and Other Discounts",
              "value": "258041"
            },
            {
              "key": "Product Returns",
              "value": "5587"
            },
            {
              "key": "Total",
              "value": "1004656"
            },
            {
              "key": "Period",
              "value": "Allowances for prior period sales"
            },
            {
              "key": "Discounts and Distribution Fees",
              "value": "-94"
            },
            {
              "key": "Government Rebates and Chargebacks",
              "value": "-2626"
            },
            {
              "key": "Assistance and Other Discounts",
              "value": "0"
            },
            {
              "key": "Product Returns",
              "value": "0"
            },
            {
              "key": "Total",
              "value": "-2725"
            },
            {
              "key": "Period",
              "value": "Credits/payments for current period sales"
            },
            {
              "key": "Discounts and Distribution Fees",
              "value": "-97085"
            },
            {
              "key": "Government Rebates and Chargebacks",
              "value": "-509430"
            },
            {
              "key": "Assistance and Other Discounts",
              "value": "-248300"
            },
            {
              "key": "Product Returns",
              "value": "0"
            },
            {
              "key": "Total",
              "value": "-854815"
            },
            {
              "key": "Period",
              "value": "Credits/payments for prior period sales"
            },
            {
              "key": "Discounts and Distribution Fees",
              "value": "-12160"
            },
            {
              "key": "Government Rebates and Chargebacks",
              "value": "-59834"
            },
            {
              "key": "Assistance and Other Discounts",
              "value": "-8230"
            },
            {
              "key": "Product Returns",
              "value": "-3961"
            },
            {
              "key": "Total",
              "value": "-84185"
            },
            {
              "key": "Period",
              "value": "Balance at December 31, 2022"
            },
            {
              "key": "Discounts and Distribution Fees",
              "value": "25316"
            },
            {
              "key": "Government Rebates and Chargebacks",
              "value": "148465"
            },
            {
              "key": "Assistance and Other Discounts",
              "value": "25580"
            },
            {
              "key": "Product Returns",
              "value": "6366"
            },
            {
              "key": "Total",
              "value": "205727"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 102,
          "title": "Novartis and Lilly Agreements",
          "data": [
            {
              "key": "Novartis agreement details",
              "value": "Novartis is responsible for all costs related to the development and commercialization of capmatinib."
            },
            {
              "key": "Novartis royalties",
              "value": "Royalties are payable until the expiration of the last valid claim of the licensed patent rights, regulatory exclusivity expiration, or a specified period from first commercial sale."
            },
            {
              "key": "Novartis milestone and contract revenue (2020-2022)",
              "value": "$60.0 million, $0.0 million, and $170.0 million for 2022, 2021, and 2020."
            },
            {
              "key": "Novartis product royalty revenues (JAKAVI)",
              "value": "$331.6 million, $338.0 million, and $277.9 million for 2022, 2021, and 2020."
            },
            {
              "key": "Novartis product royalty revenues (TABRECTA)",
              "value": "$15.4 million, $10.4 million, and $4.1 million for 2022, 2021, and 2020."
            },
            {
              "key": "Lilly agreement details",
              "value": "Lilly has exclusive worldwide development and commercialization rights to JAK inhibitor baricitinib."
            },
            {
              "key": "Lilly royalties",
              "value": "Tiered, double-digit royalties on future global sales with rates up to the mid-twenties."
            },
            {
              "key": "Lilly regulatory milestones recognized",
              "value": "$40.0 million for FDA approval of OLUMIANT, $20.0 million for European approval, and $10.0 million for Japanese approval."
            },
            {
              "key": "Lilly agreement duration",
              "value": "Agreement continues until Lilly has no royalty payment obligations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 106,
          "title": "Collaboration and License Agreement with Syros Pharmaceuticals",
          "data": [
            {
              "key": "Syros Agreement Details",
              "value": "In January 2018, entered into a Target Discovery, Research Collaboration and Option Agreement with Syros Pharmaceuticals to identify therapeutic targets in myeloproliferative neoplasms."
            },
            {
              "key": "Total Potential Payments",
              "value": "Up to $54.0 million in target selection and option exercise fees; up to $50.0 million in development and regulatory milestones; up to $65.0 million in sales milestones."
            },
            {
              "key": "Syros Common Stock Purchase",
              "value": "Purchased 0.8 million shares for $10.0 million in 2018; Additional 0.1 million shares for $1.4 million."
            },
            {
              "key": "Stock Split Adjustment",
              "value": "In September 2022, Syros conducted a one-for-ten reverse stock split."
            },
            {
              "key": "Fair Market Value 2022",
              "value": "$0.3 million"
            },
            {
              "key": "Fair Market Value 2021",
              "value": "$3.1 million"
            },
            {
              "key": "Unrealized Losses",
              "value": "Recorded unrealized losses of $2.7 million (2022), $7.1 million (2021), and unrealized gain of $3.7 million (2020)."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 59,
          "title": "Discussion and Analysis of Financial Condition and Results of Operations",
          "data": [
            {
              "key": "Anticipated increase in R&D expenditures",
              "value": "The company anticipates increased expenditures due to drug discovery, development, preclinical tests, and clinical trials."
            },
            {
              "key": "Significant funding for development",
              "value": "Development of drug products will require significant funds for research, testing, regulatory approvals, manufacturing, and marketing."
            },
            {
              "key": "Revenue uncertainty",
              "value": "The company has no current drug products generating significant revenues, with uncertainty regarding future profitability."
            },
            {
              "key": "Need for additional capital",
              "value": "The company may need to raise additional capital to fund its business plan and research and development efforts."
            },
            {
              "key": "Factors affecting funding",
              "value": "Factors include acquisitions, revenues generated, research changes, testing results, co-development costs, facility needs, corporate relationships, competition, and patent costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 79,
          "title": "Capital Expenditures and Investments Analysis",
          "data": [
            {
              "key": "marketable_securities_investment",
              "value": "$79.9 million"
            },
            {
              "key": "capital_expenditures_current_year",
              "value": "$77.8 million"
            },
            {
              "key": "net_cash_used_in_investing_activities",
              "value": "$207.7 million"
            },
            {
              "key": "purchases_of_marketable_securities",
              "value": "$235.2 million"
            },
            {
              "key": "capital_expenditures_previous_year",
              "value": "$181.0 million"
            },
            {
              "key": "purchase_of_long_term_equity_investments",
              "value": "$33.5 million"
            },
            {
              "key": "sale_of_marketable_securities",
              "value": "$231.5 million"
            },
            {
              "key": "sale_of_long_term_investment",
              "value": "$10.5 million"
            },
            {
              "key": "financing_activities_investment_2022",
              "value": "-$0.8 million"
            },
            {
              "key": "financing_activities_investment_2021",
              "value": "$6.2 million"
            },
            {
              "key": "agreement_purchase_property",
              "value": "$50.0 million"
            },
            {
              "key": "credit_facility_amount",
              "value": "$500.0 million"
            },
            {
              "key": "credit_facility_increase_option",
              "value": "$250.0 million"
            },
            {
              "key": "marketable_securities_total",
              "value": "$287.5 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 90,
          "title": "Property and Equipment Accounting",
          "data": [
            {
              "key": "Description",
              "value": "Property and equipment, net is stated at cost, less accumulated depreciation and amortization."
            },
            {
              "key": "Depreciation Method",
              "value": "Straight-line method"
            },
            {
              "key": "Estimated useful life",
              "value": "89 years"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_expenditure",
          "page": 109,
          "title": "Property and Equipment Statement",
          "data": [
            {
              "key": "Total gross assets 2021",
              "value": "899,640"
            },
            {
              "key": "Total gross assets 2022",
              "value": "952,124"
            },
            {
              "key": "Net property and equipment 2021",
              "value": "723,920"
            },
            {
              "key": "Net property and equipment 2022",
              "value": "739,310"
            },
            {
              "key": "Largest asset category 2022",
              "value": "Building and leasehold improvements"
            },
            {
              "key": "Depreciation expense 2022",
              "value": "46.3 million"
            },
            {
              "key": "Depreciation expense 2021",
              "value": "36.3 million"
            },
            {
              "key": "Depreciation expense 2020",
              "value": "29.6 million"
            },
            {
              "key": "Finance lease liability 2022",
              "value": "31.1 million"
            },
            {
              "key": "Finance lease right-of-use asset 2022",
              "value": "29.1 million"
            },
            {
              "key": "Cash purchase of land in Yverdon",
              "value": "4.8 million"
            },
            {
              "key": "Capitalized building costs Yverdon",
              "value": "176.2 million"
            },
            {
              "key": "Capitalized laboratory equipment Yverdon",
              "value": "79.7 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 109,
          "title": "Lease Liabilities Comparison 2021-2022",
          "data": [
            {
              "key": "Operating lease liabilities 2021",
              "value": "10,554"
            },
            {
              "key": "Operating lease liabilities 2022",
              "value": "8,195"
            },
            {
              "key": "Finance lease liabilities 2021",
              "value": "2,635"
            },
            {
              "key": "Finance lease liabilities 2022",
              "value": "3,179"
            },
            {
              "key": "Total lease liabilities 2021",
              "value": "13,189"
            },
            {
              "key": "Total lease liabilities 2022",
              "value": "11,374"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 115,
          "title": "Tax Provision Analysis",
          "data": [
            {
              "key": "Current Federal Provision (2022)",
              "value": "90088"
            },
            {
              "key": "Current State Provision (2022)",
              "value": "38136"
            },
            {
              "key": "Current Foreign Provision (2022)",
              "value": "3141"
            },
            {
              "key": "Subtotal Current Provision (2022)",
              "value": "131365"
            },
            {
              "key": "Deferred Federal Provision (2022)",
              "value": "62107"
            },
            {
              "key": "Deferred State Provision (2022)",
              "value": "-3709"
            },
            {
              "key": "Deferred Foreign Provision (2022)",
              "value": "-1307"
            },
            {
              "key": "Subtotal Deferred Provision (2022)",
              "value": "57091"
            },
            {
              "key": "Total Provision for Income Taxes (2022)",
              "value": "188456"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 29,
          "title": "Clinical Trials and FDA Approval Process",
          "data": [
            {
              "key": "Clinical Trials Description",
              "value": "Clinical trials involve administration of investigational drugs to human subjects under qualified supervision and in accordance with Good Clinical Practice."
            },
            {
              "key": "Phases of Clinical Trials",
              "value": "Phases I, II, and III, each with specific objectives and populations."
            },
            {
              "key": "Phase I Objectives",
              "value": "Evaluate safety, dosage tolerance, metabolism, distribution, and excretion."
            },
            {
              "key": "Phase II Objectives",
              "value": "Evaluate dosage tolerance, identify adverse effects, and preliminary efficacy evidence."
            },
            {
              "key": "Phase III Objectives",
              "value": "Further evaluate efficacy and safety in expanded patient populations."
            },
            {
              "key": "Submit to FDA",
              "value": "Protocols must be submitted to the FDA as part of the IND."
            },
            {
              "key": "Potential FDA Actions",
              "value": "FDA may suspend clinical trials if significant risks are found."
            },
            {
              "key": "Special Protocol Assessment (SPA)",
              "value": "Provides agreement on trial design that can form basis for effectiveness claim."
            },
            {
              "key": "Post-Approval Trials",
              "value": "May require further studies to monitor side effects and expand indications."
            },
            {
              "key": "Cost and Time Uncertainty",
              "value": "Variability in time and costs for clinical trials can complicate predictions."
            },
            {
              "key": "Factors Affecting Trials",
              "value": "Including slow patient enrollment and potential delays in approvals."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 68,
          "title": "Market for Registrant’s Common Equity and Stockholder Matters",
          "data": [
            {
              "key": "Common Stock Symbol",
              "value": "INCY"
            },
            {
              "key": "Par Value per Share",
              "value": "$0.001"
            },
            {
              "key": "Number of Stockholders",
              "value": "115"
            },
            {
              "key": "Dividend Policy",
              "value": "No dividends declared or paid, no plans for future dividends"
            },
            {
              "key": "Summary of Financial Condition",
              "value": "Discussion of financial performance and liquidity compared year ended December 31, 2022 to 2021."
            },
            {
              "key": "Company Overview",
              "value": "Incyte is focused on proprietary therapeutics discovery and development."
            },
            {
              "key": "Product Revenue Dependency",
              "value": "Substantial dependency on sales from JAKAFI"
            },
            {
              "key": "Research and Development Focus",
              "value": "Investments in R&D to develop new product candidates."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Operational and financial performance risks due to pandemic."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 74,
          "title": "Acquisition-related contingent consideration and revenue breakdown",
          "data": [
            {
              "key": "Contingent consideration fair value measurement basis",
              "value": "Based on projected future net revenues of ICLUSIG in the EU"
            },
            {
              "key": "Discount rate for fair value",
              "value": "10%"
            },
            {
              "key": "Net income 2022",
              "value": "$340.7 million"
            },
            {
              "key": "Net income 2021",
              "value": "$948.6 million"
            },
            {
              "key": "Basic net income 2022",
              "value": "$1.53"
            },
            {
              "key": "Diluted net income 2022",
              "value": "$1.52"
            },
            {
              "key": "Basic net income 2021",
              "value": "$4.30"
            },
            {
              "key": "Diluted net income 2021",
              "value": "$4.27"
            },
            {
              "key": "Benefit from income taxes 2021",
              "value": "$569.0 million"
            },
            {
              "key": "Increase in net income from tax benefit 2021",
              "value": "$2.58 per basic share, $2.56 per diluted share"
            },
            {
              "key": "Total product revenues 2022",
              "value": "$2746.9 million"
            },
            {
              "key": "Total product revenues 2021",
              "value": "$2322.0 million"
            },
            {
              "key": "Total revenues 2022",
              "value": "$3394.6 million"
            },
            {
              "key": "Total revenues 2021",
              "value": "$2986.3 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 76,
          "title": "Financial Performance of Contract Revenues",
          "data": [
            {
              "key": "Total regulatory milestones achieved",
              "value": "$135.0 million"
            },
            {
              "key": "Upfront payment upon transfer of intellectual property",
              "value": "$30.0 million"
            },
            {
              "key": "Sales milestone achieved",
              "value": "$50.0 million"
            },
            {
              "key": "Regulatory milestone achieved",
              "value": "$10.0 million"
            },
            {
              "key": "Upfront payment received in 2021",
              "value": "$35.0 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 76,
          "title": "Cost Breakdown For the Year Ended December 31",
          "data": [
            {
              "key": "Product costs (2022)",
              "value": "$57.1 million"
            },
            {
              "key": "Product costs (2021)",
              "value": "$21.0 million"
            },
            {
              "key": "Salary and benefits (2022)",
              "value": "$9.5 million"
            },
            {
              "key": "Salary and benefits (2021)",
              "value": "$7.2 million"
            },
            {
              "key": "Stock compensation (2022)",
              "value": "$2.7 million"
            },
            {
              "key": "Stock compensation (2021)",
              "value": "$1.7 million"
            },
            {
              "key": "Royalty expense (2022)",
              "value": "$116.2 million"
            },
            {
              "key": "Royalty expense (2021)",
              "value": "$99.6 million"
            },
            {
              "key": "Amortization (2022)",
              "value": "$21.5 million"
            },
            {
              "key": "Amortization (2021)",
              "value": "$21.5 million"
            },
            {
              "key": "Total cost of product revenues (2022)",
              "value": "$207.0 million"
            },
            {
              "key": "Total cost of product revenues (2021)",
              "value": "$151.0 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 76,
          "title": "Research and Development Expenses Breakdown",
          "data": [
            {
              "key": "Salary and benefits (2022)",
              "value": "$345.6 million"
            },
            {
              "key": "Salary and benefits (2021)",
              "value": "$306.0 million"
            },
            {
              "key": "Stock compensation (2022)",
              "value": "$112.5 million"
            },
            {
              "key": "Stock compensation (2021)",
              "value": "$114.3 million"
            },
            {
              "key": "Clinical research (2022)",
              "value": "$978.9 million"
            },
            {
              "key": "Clinical research (2021)",
              "value": "$902.3 million"
            },
            {
              "key": "Occupancy and other costs (2022)",
              "value": "$148.9 million"
            },
            {
              "key": "Occupancy and other costs (2021)",
              "value": "$135.6 million"
            },
            {
              "key": "Total R&D expenses (2022)",
              "value": "$1585.9 million"
            },
            {
              "key": "Total R&D expenses (2021)",
              "value": "$1458.2 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 77,
          "title": "Selling, General and Administrative Expenses Comparison 2022-2021",
          "data": [
            {
              "key": "Salary and benefits related",
              "value": "269.1"
            },
            {
              "key": "Stock compensation",
              "value": "73.2"
            },
            {
              "key": "Other contract services and outside",
              "value": "659.8"
            },
            {
              "key": "Total selling, general and administrative",
              "value": "1002.1"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 78,
          "title": "Financial Performance For the Years Ended, December 31, (in millions)",
          "data": [
            {
              "key": "Total loss 2021",
              "value": "$24.1 million"
            },
            {
              "key": "Total loss 2022",
              "value": "$87.6 million"
            },
            {
              "key": "Syndax 2021",
              "value": "$6.3 million"
            },
            {
              "key": "Syndax 2022",
              "value": "$5.1 million"
            },
            {
              "key": "Merus 2021",
              "value": "$48.1 million"
            },
            {
              "key": "Merus 2022",
              "value": "-$58.0 million"
            },
            {
              "key": "Calithera 2021",
              "value": "-$7.3 million"
            },
            {
              "key": "Calithera 2022",
              "value": "-$0.9 million"
            },
            {
              "key": "MorphoSys 2021",
              "value": "-$68.7 million"
            },
            {
              "key": "MorphoSys 2022",
              "value": "-$21.2 million"
            },
            {
              "key": "Total companies showing loss",
              "value": "5 out of 7"
            },
            {
              "key": "Overview",
              "value": "Most companies showed losses in both years. Only Syndax maintained positive figures in both years."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 80,
          "title": "Financial Statements Table of Contents",
          "data": [
            {
              "key": "Document",
              "value": "Ernst & Young LLP, Balance Sheets"
            },
            {
              "key": "Date",
              "value": "December 31, 2022 and 2021"
            },
            {
              "key": "Page",
              "value": "80-83"
            },
            {
              "key": "Document",
              "value": "Statements of Operations"
            },
            {
              "key": "Period",
              "value": "years ended December 31, 2022, 2021 and 2020"
            },
            {
              "key": "Page",
              "value": "84"
            },
            {
              "key": "Document",
              "value": "Statements of Comprehensive Income (Loss)"
            },
            {
              "key": "Period",
              "value": "years ended December 31, 2022, 2021 and 2020"
            },
            {
              "key": "Page",
              "value": "85"
            },
            {
              "key": "Document",
              "value": "Statements of Stockholders' Equity"
            },
            {
              "key": "Period",
              "value": "years ended December 31, 2022, 2021 and 2020"
            },
            {
              "key": "Page",
              "value": "86"
            },
            {
              "key": "Document",
              "value": "Statements of Cash Flows"
            },
            {
              "key": "Period",
              "value": "years ended December 31, 2022, 2021 and 2020"
            },
            {
              "key": "Page",
              "value": "87"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 81,
          "title": "Report of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Opinion on the Financial Statements",
              "value": "We have audited the accompanying consolidated balance sheets of Incyte Corporation as of December 31, 2022 and 2021."
            },
            {
              "key": "Audit Opinion",
              "value": "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company."
            },
            {
              "key": "Audit Standards",
              "value": "We conducted our audits in accordance with the standards of the PCAOB."
            },
            {
              "key": "Critical Audit Matters",
              "value": "Allowances for rebates owed pursuant to the Medicaid Drug Rebate Program in the U.S."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 84,
          "title": "Balance Sheet",
          "data": [
            {
              "key": "Total assets",
              "value": "$5,840,984"
            },
            {
              "key": "Previous total assets",
              "value": "$4,933,352"
            },
            {
              "key": "Cash and cash equivalents",
              "value": "$2,951,422"
            },
            {
              "key": "Previous cash and cash equivalents",
              "value": "$2,057,440"
            },
            {
              "key": "Total liabilities",
              "value": "$1,470,865"
            },
            {
              "key": "Previous total liabilities",
              "value": "$1,163,348"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 85,
          "title": "Financial Statement of Operations",
          "data": [
            {
              "key": "Total revenues",
              "value": "$3.39B"
            },
            {
              "key": "Net income (loss)",
              "value": "$340.66M"
            },
            {
              "key": "Research and development expenses",
              "value": "$1.59B"
            },
            {
              "key": "Selling, general and administrative expenses",
              "value": "$1.00B"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 86,
          "title": "Net Income and Comprehensive Income Statement",
          "data": [
            {
              "key": "Net Income (Loss)",
              "value": "2022: 340660, 2021: 948581, 2020: -295697"
            },
            {
              "key": "Foreign currency translation gain (loss)",
              "value": "2022: 13065, 2021: -2959, 2020: 8450"
            },
            {
              "key": "Unrealized (loss) gain on marketable securities, net of tax",
              "value": "2022: -3918, 2021: -1289, 2020: 95"
            },
            {
              "key": "Defined benefit pension gain (loss), net of tax",
              "value": "2022: 25376, 2021: 154, 2020: -8363"
            },
            {
              "key": "Other comprehensive income (loss)",
              "value": "2022: 34523, 2021: -4094, 2020: 182"
            },
            {
              "key": "Comprehensive income (loss)",
              "value": "2022: 375183, 2021: 944487, 2020: -295515"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 92,
          "title": "Financial Performance Indicators",
          "data": [
            {
              "key": "Net Income (Loss) Per Share",
              "value": "Basic and diluted net income (loss) per share calculated by dividing the net income (loss) by the weighted average number of shares of common stock."
            },
            {
              "key": "Accumulated Other Comprehensive Income (Loss)",
              "value": "Consists of unrealized gains or losses on marketable debt securities classified as available-for-sale, foreign currency translation gains/losses, and unrecognized actuarial gains/losses."
            },
            {
              "key": "Revenue Recognition",
              "value": "Revenue-generating contracts assessed under ASC 606 to identify distinct performance obligations and allocate transaction price."
            },
            {
              "key": "Product Revenues",
              "value": "Product revenues from sales of JAKAFI, OPZELURA, PEMAZYRE in the U.S. and Europe, recognized at the point of satisfying performance obligation."
            },
            {
              "key": "Customer Credits",
              "value": "Customers offered consideration including allowances, service fees, and prompt payment discounts which are deducted from total product sales."
            },
            {
              "key": "Rebates and Discounts",
              "value": "Allowances for mandated discounts under programs such as Medicaid and based on contractual agreements."
            },
            {
              "key": "Buy-down Program for OPZELURA",
              "value": "Full buy-down programs initiated for OPZELURA ended effective January 31, 2023."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 98,
          "title": "Fair Value Measurements by Level",
          "data": [
            {
              "key": "Cash and cash equivalents",
              "value": "$2,951,422"
            },
            {
              "key": "Debt securities (government)",
              "value": "$287,543"
            },
            {
              "key": "Long term investments (Note 7)",
              "value": "$133,676"
            },
            {
              "key": "Total assets",
              "value": "$3,372,641"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 98,
          "title": "Fair Value Measurements and Asset Classifications",
          "data": [
            {
              "key": "Cash and cash equivalents",
              "value": "$2,057,440"
            },
            {
              "key": "Debt securities (government)",
              "value": "$290,752"
            },
            {
              "key": "Long term investments (Note 7)",
              "value": "$221,266"
            },
            {
              "key": "Total assets",
              "value": "$2,569,458"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 98,
          "title": "Fair Value Measurement Hierarchy of Liabilities",
          "data": [
            {
              "key": "Acquisition-related contingent consideration",
              "value": "$221,000"
            },
            {
              "key": "Total liabilities",
              "value": "$221,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 110,
          "title": "Lease Liabilities Overview",
          "data": [
            {
              "key": "Category",
              "value": "Noncurrent"
            },
            {
              "key": "Operating lease liabilities 2022",
              "value": "14,109"
            },
            {
              "key": "Operating lease liabilities 2021",
              "value": "15,608"
            },
            {
              "key": "Finance lease liabilities 2022",
              "value": "30,083"
            },
            {
              "key": "Finance lease liabilities 2021",
              "value": "31,632"
            },
            {
              "key": "Total lease liabilities 2022",
              "value": "55,566"
            },
            {
              "key": "Total lease liabilities 2021",
              "value": "60,429"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 111,
          "title": "Intangible Assets and Goodwill",
          "data": [
            {
              "key": "Finite-lived intangible assets: Licensed IP - gross carrying amount year 1",
              "value": "$271,000"
            },
            {
              "key": "Finite-lived intangible assets: Licensed IP - accumulated amortization year 1",
              "value": "$141,781"
            },
            {
              "key": "Finite-lived intangible assets: Licensed IP - net carrying amount year 1",
              "value": "$129,219"
            },
            {
              "key": "Finite-lived intangible assets: Licensed IP - gross carrying amount year 2",
              "value": "$271,000"
            },
            {
              "key": "Finite-lived intangible assets: Licensed IP - accumulated amortization year 2",
              "value": "$120,245"
            },
            {
              "key": "Finite-lived intangible assets: Licensed IP - net carrying amount year 2",
              "value": "$150,755"
            },
            {
              "key": "Amortization expense for years ended December 31",
              "value": "$21.5 million"
            },
            {
              "key": "Total Accrued and Other Current Liabilities 2021",
              "value": "$533,595"
            },
            {
              "key": "Total Accrued and Other Current Liabilities 2022",
              "value": "$701,053"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 116,
          "title": "Deferred Tax Assets and Liabilities",
          "data": [
            {
              "key": "Net operating loss carry forwards",
              "value": "182,193"
            },
            {
              "key": "Federal and state research credits",
              "value": "17,141"
            },
            {
              "key": "Capitalized research and development",
              "value": "265,140"
            },
            {
              "key": "Deferred revenue and accruals",
              "value": "72,657"
            },
            {
              "key": "Non-cash compensation",
              "value": "83,138"
            },
            {
              "key": "Acquisition-related contingent consideration",
              "value": "30,483"
            },
            {
              "key": "Intangibles, net",
              "value": "257,614"
            },
            {
              "key": "Long term investments",
              "value": "54,662"
            },
            {
              "key": "Other",
              "value": "9,600"
            },
            {
              "key": "Total gross deferred tax assets",
              "value": "972,628"
            },
            {
              "key": "Less valuation allowance",
              "value": "-472,125"
            },
            {
              "key": "Net deferred tax assets",
              "value": "500,503"
            },
            {
              "key": "Property and equipment",
              "value": "-33,683"
            },
            {
              "key": "Other liabilities",
              "value": "-8,879"
            },
            {
              "key": "Total gross deferred tax liabilities",
              "value": "-42,562"
            },
            {
              "key": "Net deferred tax assets",
              "value": "457,941"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 117,
          "title": "Tax Balance Reconciliation",
          "data": [
            {
              "key": "Balance at beginning of year",
              "value": "62359"
            },
            {
              "key": "Additions related to prior periods",
              "value": "5027"
            },
            {
              "key": "Reductions related to prior periods",
              "value": "-2087"
            },
            {
              "key": "Additions related to current period",
              "value": "8290"
            },
            {
              "key": "Settlements",
              "value": "-104"
            },
            {
              "key": "Reductions due to lapse of applicable",
              "value": "-356"
            },
            {
              "key": "Currency translation adjustment",
              "value": "-89"
            },
            {
              "key": "Balance at end of year",
              "value": "73040"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 117,
          "title": "(in thousands, except per share data)",
          "data": [
            {
              "key": "2022 Basic Net Income",
              "value": "340660"
            },
            {
              "key": "2022 Basic Shares Outstanding",
              "value": "222004"
            },
            {
              "key": "2022 Basic EPS",
              "value": "1.53"
            },
            {
              "key": "2022 Diluted Net Income",
              "value": "340660"
            },
            {
              "key": "2022 Diluted Shares Outstanding",
              "value": "223958"
            },
            {
              "key": "2022 Diluted EPS",
              "value": "1.52"
            },
            {
              "key": "2021 Basic Net Income",
              "value": "948581"
            },
            {
              "key": "2021 Basic Shares Outstanding",
              "value": "220428"
            },
            {
              "key": "2021 Basic EPS",
              "value": "4.30"
            },
            {
              "key": "2021 Diluted Net Income",
              "value": "948581"
            },
            {
              "key": "2021 Diluted Shares Outstanding",
              "value": "222074"
            },
            {
              "key": "2021 Diluted EPS",
              "value": "4.27"
            },
            {
              "key": "2020 Basic Net Income",
              "value": "-295697"
            },
            {
              "key": "2020 Basic Shares Outstanding",
              "value": "218073"
            },
            {
              "key": "2020 Basic EPS",
              "value": "-1.36"
            },
            {
              "key": "2020 Diluted Net Income",
              "value": "-295697"
            },
            {
              "key": "2020 Diluted Shares Outstanding",
              "value": "218073"
            },
            {
              "key": "2020 Diluted EPS",
              "value": "-1.36"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 117,
          "title": "Outstanding Stock Options and Awards",
          "data": [
            {
              "key": "Outstanding stock options and awards 2023",
              "value": "10946703"
            },
            {
              "key": "Outstanding stock options and awards 2022",
              "value": "10106837"
            },
            {
              "key": "Outstanding stock options and awards 2021",
              "value": "15274871"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 120,
          "title": "Financial Performance and Contingencies",
          "data": [
            {
              "key": "Consolidated Leverage Ratio",
              "value": "Varying from 1.125% to 1.875%"
            },
            {
              "key": "Commitment Fees",
              "value": "Range from 0.150% to 0.225% per annum based on consolidated leverage ratio"
            },
            {
              "key": "Compliance Status",
              "value": "In compliance with all financial and operational covenants as of December 31, 2022"
            },
            {
              "key": "Litigation Risks",
              "value": "Involvement in lawsuits and other disputes including commercial, intellectual property, regulatory, and employment matters"
            },
            {
              "key": "Total Revenues in US - 2022",
              "value": "$3.2 billion"
            },
            {
              "key": "Total Revenues in Europe - 2022",
              "value": "$147.0 million"
            },
            {
              "key": "Total Revenues in US - 2021",
              "value": "$2.9 billion"
            },
            {
              "key": "Total Revenues in Europe - 2021",
              "value": "$124.1 million"
            },
            {
              "key": "Total Revenues in US - 2020",
              "value": "$2.6 billion"
            },
            {
              "key": "Total Revenues in Europe - 2020",
              "value": "$105.0 million"
            },
            {
              "key": "Property and Equipment in US - 2022",
              "value": "$442.0 million"
            },
            {
              "key": "Property and Equipment in Europe - 2022",
              "value": "$295.8 million"
            },
            {
              "key": "Property and Equipment in Japan - 2022",
              "value": "$1.5 million"
            },
            {
              "key": "Evaluation of Disclosure Controls",
              "value": "Designed to ensure timely and accurate disclosure as per SEC rules."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 130,
          "title": "Stock Price Performance Graph",
          "data": [
            {
              "key": "Cumulative Total Stockholder Return",
              "value": "100"
            },
            {
              "key": "Investment on 12/31/2017",
              "value": "$100"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": false,
      "elements": []
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": false,
      "elements": []
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 4,
          "title": "Risk Factors Related to Product Commercialization",
          "data": [
            {
              "key": "COVID-19 pandemic impact",
              "value": "Potential effects on economic conditions and business performance due to the pandemic."
            },
            {
              "key": "Commercialization risks",
              "value": "Successful commercialization of drug products and candidates."
            },
            {
              "key": "Coverage and reimbursement risks",
              "value": "Ability to obtain and maintain coverage from health authorities and insurers."
            },
            {
              "key": "Sales and marketing capability risks",
              "value": "Establishing effective sales, marketing, and distribution capabilities."
            },
            {
              "key": "Manufacturing reliance risk",
              "value": "Reliance on other parties could lead to short supply and increased costs."
            },
            {
              "key": "Regulatory approval risks",
              "value": "Maintaining regulatory approvals for products."
            },
            {
              "key": "Market share risks",
              "value": "Achieving significant market share for profitability."
            },
            {
              "key": "Legal compliance risks",
              "value": "Risk of penalties for marketing violations."
            },
            {
              "key": "Drug development risks",
              "value": "Risks in discovering and commercializing drug candidates."
            },
            {
              "key": "Development delays risks",
              "value": "Unanticipated delays or discontinuations in R&D."
            },
            {
              "key": "Clinical trial risks",
              "value": "Past results may not indicate future outcomes."
            },
            {
              "key": "Adverse safety findings",
              "value": "Risks associated with safety findings during trials."
            },
            {
              "key": "Regulatory approval delays",
              "value": "Delays in obtaining approvals."
            },
            {
              "key": "Third-party reliance risks",
              "value": "Risks relating to reliance on third-party manufacturers and collaborators."
            },
            {
              "key": "Product liability coverage",
              "value": "Maintaining adequate insurance coverage."
            },
            {
              "key": "Technological and competitive risks",
              "value": "Impact of technological advances and competition."
            },
            {
              "key": "Pricing and reimbursement changes",
              "value": "Changes in market pricing and reimbursement."
            },
            {
              "key": "Government healthcare reforms",
              "value": "Efforts to control or cap drug pricing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 5,
          "title": "Summary Risk Factors",
          "data": [
            {
              "key": "competition",
              "value": "competition to develop and commercialize similar drug products"
            },
            {
              "key": "patent_protection",
              "value": "our ability to obtain and maintain patent protection and freedom to operate for our discoveries"
            },
            {
              "key": "changing_laws",
              "value": "the impact of changing laws on our patent portfolio"
            },
            {
              "key": "litigation_developments",
              "value": "developments in and expenses relating to litigation"
            },
            {
              "key": "licensing_technology",
              "value": "our ability to in-license drug candidates or other technology"
            },
            {
              "key": "production_delays",
              "value": "unanticipated delays or changes in plans or regulatory agency interactions"
            },
            {
              "key": "integration_success",
              "value": "our ability to integrate successfully acquired businesses, development programs or technology"
            },
            {
              "key": "capital_access",
              "value": "our ability to obtain additional capital when needed"
            },
            {
              "key": "net_cash_fluctuations",
              "value": "fluctuations in net cash provided and used by operating, financing and investing activities"
            },
            {
              "key": "accounting_risk",
              "value": "our ability to analyze the effects of new accounting pronouncements"
            },
            {
              "key": "profitability_risks",
              "value": "risks relating to our ability to sustain profitability"
            },
            {
              "key": "public_health_risks",
              "value": "risks related to public health pandemics, natural disasters, or geopolitical events"
            },
            {
              "key": "investment_advice",
              "value": "you should carefully consider all of the information in this report and risk factors before investing"
            },
            {
              "key": "dependence_on_product",
              "value": "We depend heavily on JAKAFI/JAKAVI and need to maintain revenues from it"
            },
            {
              "key": "coverage_reimbursement_risks",
              "value": "We or our collaborators may be unable to obtain or maintain coverage and reimbursement"
            },
            {
              "key": "limited_pharmacies_risks",
              "value": "A limited number of pharmacies and wholesalers represent a significant portion of revenues"
            },
            {
              "key": "sales_marketing",
              "value": "If we cannot maintain effective sales, marketing, and distribution capabilities, we may not commercialize products"
            },
            {
              "key": "regulatory_compliance_risks",
              "value": "If we fail to comply with laws and regulations, we could lose marketing approval or face governmental activities"
            },
            {
              "key": "product_liability_claims",
              "value": "If our products harm patients, it could negatively impact regulatory approvals or lead to liability claims"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 6,
          "title": "Legal and Regulatory Risks",
          "data": [
            {
              "key": "Violation of laws and regulations",
              "value": "Marketing products in violation of laws may result in civil or criminal penalties."
            },
            {
              "key": "Competitive pressure",
              "value": "Competition may harm business and revenue."
            },
            {
              "key": "Impact of COVID-19 and geopolitical events",
              "value": "Adverse effects from the COVID-19 pandemic could affect business operations."
            },
            {
              "key": "Failure in drug development",
              "value": "Unsuccessful discovery and development of drug candidates may waste significant time and money."
            },
            {
              "key": "Regulatory approval challenges",
              "value": "Inability to obtain regulatory approval could hinder commercialization of drug candidates."
            },
            {
              "key": "Health care reform impacts",
              "value": "Changes in health care reform could affect profitability and viability of products."
            },
            {
              "key": "Collaboration conflicts",
              "value": "Conflicts with collaborators or termination of agreements could limit future development."
            },
            {
              "key": "Inability to establish collaborations",
              "value": "Failure to secure collaborations could diminish future revenue prospects."
            },
            {
              "key": "Uncertain commercialization of approved drugs",
              "value": "Commercialization of approved drugs may not justify investment."
            },
            {
              "key": "Market acceptance issues",
              "value": "Approved drugs may not gain acceptance among physicians and patients."
            },
            {
              "key": "Limited testing capacity",
              "value": "Dependence on others for testing may result in delays and increased costs."
            },
            {
              "key": "Significant competition",
              "value": "Inadequate competition strategies may reduce commercial opportunities."
            },
            {
              "key": "Supply chain risks",
              "value": "Reliance on external manufacturing may cause supply issues and regulatory challenges."
            },
            {
              "key": "Compliance risks",
              "value": "Non-compliance with health care regulations could lead to penalties and loss of business."
            },
            {
              "key": "Counterfeit products risk",
              "value": "Counterfeit sales by third parties could harm business reputation."
            },
            {
              "key": "Facility access risk",
              "value": "Loss of access to headquarters could negatively impact business operations."
            },
            {
              "key": "Key employee loss",
              "value": "Loss of key personnel may harm objectives and business capability."
            },
            {
              "key": "Growth management risk",
              "value": "Failure to manage growth effectively could impair product development."
            },
            {
              "key": "Acquisition risks",
              "value": "Unsuccessful acquisitions or investments may divert management focus and harm results."
            },
            {
              "key": "International operations risks",
              "value": "Operations outside the U.S. could adversely affect business."
            },
            {
              "key": "Product liability risk",
              "value": "Product liability lawsuits may cause substantial liabilities."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 7,
          "title": "Risk Factors Associated with Operations and Financial Position",
          "data": [
            {
              "key": "Hazardous Materials Liability",
              "value": "Claims relating to improper handling, storage or disposal could be costly."
            },
            {
              "key": "R&D Expenses",
              "value": "Expect significant expenses in drug discovery, impacting future profitability."
            },
            {
              "key": "Capital Raising Needs",
              "value": "Inability to raise capital may limit product portfolio expansion."
            },
            {
              "key": "Marketable Securities Risks",
              "value": "Subject to risks that could adversely affect financial position."
            },
            {
              "key": "Milestones and Collaborations",
              "value": "Failure to achieve milestones could decrease royalty revenues."
            },
            {
              "key": "Litigation Costs",
              "value": "Intellectual property arbitration could disrupt efforts and incur costs."
            },
            {
              "key": "Proprietary Information Protection",
              "value": "Inability to protect could reduce competition and revenue."
            },
            {
              "key": "Patent Term and Applications",
              "value": "Decreased patent term or refiling may reduce patent portfolio value."
            },
            {
              "key": "International Patent Protection Risks",
              "value": "Uncertain and costly, with potential for substantial expenditures."
            },
            {
              "key": "IT System Disruptions",
              "value": "Could harm business and lead to liability issues."
            },
            {
              "key": "Social Media Risks",
              "value": "Increased use could result in data security breaches and reputational damage."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 27,
          "title": "Intellectual Property and Competitive Risks",
          "data": [
            {
              "key": "litigation_risks",
              "value": "Potential litigation or proceedings may be necessary to defend against infringement claims."
            },
            {
              "key": "costs_of_litigation",
              "value": "Substantial costs may be incurred in litigation."
            },
            {
              "key": "adverse_outcomes",
              "value": "An adverse outcome could subject us to significant liability."
            },
            {
              "key": "trade_secrets_risks",
              "value": "Reliance on trade secrets and confidentiality agreements is not foolproof."
            },
            {
              "key": "competition_description",
              "value": "Intense competition from pharmaceutical, biotechnology companies, research institutions."
            },
            {
              "key": "competitor_advantages",
              "value": "Competitors may have greater resources and experience."
            },
            {
              "key": "drug_candidates_competition",
              "value": "Competition for drug candidates includes established therapies."
            },
            {
              "key": "development_challenges",
              "value": "Challenges in drug discovery and obtaining regulatory approvals."
            },
            {
              "key": "proprietary_products_development",
              "value": "Our ability to compete depends on developing proprietary products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 35,
          "title": "Risk Factors Related to Third-Party Manufacturers and Supply Chains",
          "data": [
            {
              "key": "Third-party manufacturing risks",
              "value": "The dependency on independent manufacturers who may fail to perform as required, impairing timely delivery of products."
            },
            {
              "key": "Supply chain risks",
              "value": "Risks from possible interruptions in the supply of raw materials from suppliers, particularly from Chinese-based sources."
            },
            {
              "key": "Human capital management",
              "value": "The company's commitment to promoting a culture based on scientific excellence and compliance with regulatory requirements."
            },
            {
              "key": "Compliance and safety",
              "value": "The importance of meeting environmental, health and safety regulatory requirements and maintaining a strong safety culture."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 37,
          "title": "Risks Relating to Commercialization of JAKAFI",
          "data": [
            {
              "key": "Lead Product",
              "value": "JAKAFI (ruxolitinib)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 38,
          "title": "Revenue Dependency and Regulatory Risks",
          "data": [
            {
              "key": "concern",
              "value": "Possible material harm from decreased revenues from JAKAFI."
            },
            {
              "key": "impact",
              "value": "Need to delay drug discovery and development."
            },
            {
              "key": "factors",
              "value": "Regulatory, pricing, and reimbursement issues affecting revenues."
            },
            {
              "key": "profitability_risk",
              "value": "Reduced profitability if products must be sold at lower prices."
            },
            {
              "key": "government_intervention",
              "value": "Government initiatives to manage drug costs affect pricing."
            },
            {
              "key": "international_reimbursement",
              "value": "Reimbursement negotiations are country-specific and can delay product launches."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 50,
          "title": "Risks Related to Collaborations and Commercialization of Drug Candidates",
          "data": [
            {
              "key": "risk_description",
              "value": "Risks associated with third-party payor coverage, inadequate reimbursement, conflicts with collaborators, and dependence on their development and commercialization efforts."
            },
            {
              "key": "collaboration_impacts",
              "value": "Termination of agreements with collaborators may adversely affect business and revenues."
            },
            {
              "key": "regulatory_approval_delay",
              "value": "Delays in marketing approval or modifications to product labels could reduce potential revenue."
            },
            {
              "key": "litigation_risks",
              "value": "Disputes may lead to litigation or arbitration, diverting management resources."
            },
            {
              "key": "collaboration_strategy",
              "value": "Success depends on finding suitable collaborators, without which business could be adversely affected."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 52,
          "title": "Risk Factors Related to Drug Development and Commercialization",
          "data": [
            {
              "key": "Impact of Licensing Agreements",
              "value": "The potential termination of agreements by collaborators and licensers may adversely affect business operations."
            },
            {
              "key": "Conflicts with Licensors",
              "value": "Conflicts could lead to delays and increased expenditures that adversely affect operations."
            },
            {
              "key": "Regulatory Approval Concerns",
              "value": "Even with regulatory approval, commercialization might not occur due to cost, time, or market acceptance issues."
            },
            {
              "key": "Market Acceptance Issues",
              "value": "Market success depends on various factors including pricing, reimbursement policies, and competition."
            },
            {
              "key": "FDA Warnings on JAKAFI",
              "value": "Updated labeling for JAKAFI includes warnings of increased risks of serious cardiovascular events."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 53,
          "title": "Risk Factors Related to Drug Development and Competition",
          "data": [
            {
              "key": "Labeling Change Risk",
              "value": "The updated labeling for OPZELURA and JAKAFI may negatively affect sales."
            },
            {
              "key": "Limited Internal Resources",
              "value": "Dependence on external parties for preclinical testing and clinical trials may cause delays and additional costs."
            },
            {
              "key": "Competition",
              "value": "Significant competition in the biotechnology and pharmaceutical industries could limit commercial opportunities."
            },
            {
              "key": "Manufacturing Dependency",
              "value": "Reliance on third parties for manufacturing could lead to supply issues and regulatory approval challenges."
            },
            {
              "key": "Regulatory Compliance Risk",
              "value": "Failure to comply with Good Manufacturing Practices may result in regulatory penalties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 57,
          "title": "International operations and business risks",
          "data": [
            {
              "key": "Risk Factors",
              "value": "International operations and business expansion plans are subject to numerous additional risks."
            },
            {
              "key": "Regulatory Risks",
              "value": "Complexity of laws and regulations in multiple jurisdictions."
            },
            {
              "key": "Staffing Challenges",
              "value": "Difficulties in staffing and managing operations globally."
            },
            {
              "key": "Regulatory Approvals",
              "value": "Risks associated with obtaining regulatory approvals for products."
            },
            {
              "key": "Financial Risks",
              "value": "Longer payment cycles and difficulty collecting accounts receivable."
            },
            {
              "key": "Political Conditions",
              "value": "Impact of political and economic conditions on operations."
            },
            {
              "key": "Public Health Risks",
              "value": "Effects of the COVID-19 pandemic on clinical trials and operation."
            },
            {
              "key": "Compliance Risks",
              "value": "Maintaining compliance with anti-bribery and anti-corruption laws."
            },
            {
              "key": "Foreign Currency Fluctuations",
              "value": "Revenues subject to fluctuations in foreign currency exchange rates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 58,
          "title": "Risks Relating to Product Liability and Financial Results",
          "data": [
            {
              "key": "Insurance Coverage Concern",
              "value": "Our product liability insurance policy may not fully cover our potential liabilities and could be prohibitively expensive."
            },
            {
              "key": "Self-Insurance Decision",
              "value": "As of December 30, 2017, we self-insured part of our product liability exposure via a wholly-owned subsidiary."
            },
            {
              "key": "Environmental Compliance Risk",
              "value": "Our operations involve hazardous materials, and compliance with environmental laws is costly."
            },
            {
              "key": "Business Disruptions Risk",
              "value": "Geopolitical events, natural disasters, and pandemics may adversely affect our operations."
            },
            {
              "key": "Financial Viability Concern",
              "value": "Due to past net losses, we may struggle to achieve sustained profitability."
            },
            {
              "key": "Future Expense Expectation",
              "value": "We expect to continue incurring significant expenses related to drug development."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 60,
          "title": "Financial Risks and Tax Regulations",
          "data": [
            {
              "key": "Funding Risk",
              "value": "Possibility of not being able to continue developing drug candidates without adequate funds."
            },
            {
              "key": "Dilution Risk",
              "value": "Sale of equity or equity-linked securities may dilute stockholders."
            },
            {
              "key": "Debt Financing Limitations",
              "value": "Debt arrangements could restrict operations or ability to pay dividends."
            },
            {
              "key": "Investment Risks",
              "value": "Marketable securities and long term investments subject to adverse risks."
            },
            {
              "key": "Investment Losses",
              "value": "Losses on investments in strategic alliances could affect financial position."
            },
            {
              "key": "Tax Law Changes",
              "value": "Changes in tax laws could adversely impact operations and financial condition."
            },
            {
              "key": "R&D Expenditure Policy",
              "value": "New tax regulations require capitalization of R&D expenditures affecting tax liability."
            },
            {
              "key": "Minimum Tax Legislation",
              "value": "Implementation of a new 15% alternative minimum tax could increase tax obligations."
            },
            {
              "key": "BEPS 2.0 Impact",
              "value": "Fundamental changes to international tax system could lead to increased tax rates."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 62,
          "title": "Intellectual Property Risks",
          "data": [
            {
              "key": "Potential Risks to Proprietary Technology",
              "value": "Possibility of unauthorized use and loss of revenue due to inability to adequately protect proprietary information."
            },
            {
              "key": "Patent Application Uncertainty",
              "value": "Patent applications may take years to issue and may not provide broad protection, potentially allowing others to develop competing products."
            },
            {
              "key": "Challenge from Competitors",
              "value": "Potential generic drug companies may challenge important patents, impacting revenue."
            },
            {
              "key": "Dependence on Third-Party Rights",
              "value": "Lack of control over prosecution and maintenance of important intellectual property could impede rights."
            },
            {
              "key": "Trade Secret Protection Limitations",
              "value": "Agreements with employees may not effectively protect against unauthorized use or disclosure."
            },
            {
              "key": "Impact of Patent Duration Changes",
              "value": "Changes in patent laws could shorten effective patent terms, reducing the value of the patent portfolio."
            },
            {
              "key": "Challenges Under America Invents Act",
              "value": "New challenge mechanisms may create uncertainty regarding the validity of U.S. patents."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 63,
          "title": "Legal and Regulatory Risks Regarding Patent Validity",
          "data": [
            {
              "key": "Patents Validity Risks",
              "value": "The proceedings to determine the validity of U.S. patents could lead to substantial costs and affect patent protection."
            },
            {
              "key": "FDA Approval Risks",
              "value": "If patents are invalidated, generic manufacturers might produce products before patent expiration."
            },
            {
              "key": "Changes in Patent Laws",
              "value": "Changes in laws could diminish patent value or protection scope."
            },
            {
              "key": "International Patent Protection Risks",
              "value": "Biotechnology and pharmaceutical patent law is more uncertain and costly internationally."
            },
            {
              "key": "Data Privacy and IT Risks",
              "value": "Disruptions in IT systems or data breaches could adversely affect the business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 97,
          "title": "Revenue Summary",
          "data": [
            {
              "key": "JAKAFI revenues, net",
              "value": "2409225"
            },
            {
              "key": "ICLUSIG revenues, net",
              "value": "105838"
            },
            {
              "key": "PEMAZYRE revenues, net",
              "value": "83445"
            },
            {
              "key": "MINJUVI revenues, net",
              "value": "19654"
            },
            {
              "key": "OPZELURA revenues, net",
              "value": "128735"
            },
            {
              "key": "Total product revenues",
              "value": "2746897"
            },
            {
              "key": "JAKAVI product royalty revenues",
              "value": "331575"
            },
            {
              "key": "OLUMIANT product royalty revenues",
              "value": "134547"
            },
            {
              "key": "TABRECTA product royalty revenues",
              "value": "15411"
            },
            {
              "key": "PEMAZYRE product royalty revenues",
              "value": "1205"
            },
            {
              "key": "Total product royalty revenues",
              "value": "482738"
            },
            {
              "key": "Milestone and contract revenues",
              "value": "165000"
            },
            {
              "key": "Total revenues",
              "value": "3394635"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 97,
          "title": "Government Debt Securities Valuation Summary",
          "data": [
            {
              "key": "Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Amortized Cost",
              "value": "$292580"
            },
            {
              "key": "Unrealized Losses",
              "value": "$5037"
            },
            {
              "key": "Estimated Fair Value",
              "value": "$287543"
            },
            {
              "key": "Type",
              "value": "Debt securities (government)"
            },
            {
              "key": "Date",
              "value": "December 31, 2021"
            },
            {
              "key": "Amortized Cost",
              "value": "$291871"
            },
            {
              "key": "Unrealized Losses",
              "value": "$1119"
            },
            {
              "key": "Estimated Fair Value",
              "value": "$290752"
            },
            {
              "key": "Type",
              "value": "Debt securities (government)"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 2,
          "title": "Table of Contents",
          "data": [
            {
              "key": "summary",
              "value": "This table appears to be a table of contents or index from a financial report or regulatory filing (likely a Form 10-K or similar document). It is organized into four main parts plus signatures, with each part containing multiple items. The document spans pages 19-79, with different sections covering various aspects of business operations, financial statements, corporate governance, and other required disclosures."
            },
            {
              "key": "sections",
              "value": "PART I, PART II, PART III, PART IV, SIGNATURES"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 3,
          "title": "Forward-Looking Statements",
          "data": [
            {
              "key": "content",
              "value": "This report contains forward-looking statements that involve risks and uncertainties relating to future periods, future events or our future operating or financial plans or performance. These forward-looking statements include various aspects regarding drug candidates such as JAKAFI®/JAKAVI®, PEMAZYRE®, ICLUSIG®, MONJUVI®, and OPZELURA™, plans for operational development outside the U.S., clinical trials, collaboration agreements, regulatory approval processes, financial expectations, and profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 14,
          "title": "Clinical Trials and Drug Development Updates",
          "data": [
            {
              "key": "Study Name",
              "value": "FIGHT-209"
            },
            {
              "key": "Cancer Type",
              "value": "Glioblastoma"
            },
            {
              "key": "Status",
              "value": "Phase II trials initiated"
            },
            {
              "key": "Study Name",
              "value": "FIGHT-210"
            },
            {
              "key": "Cancer Type",
              "value": "Non-small cell lung cancer"
            },
            {
              "key": "Treatment",
              "value": "pemigatinib"
            },
            {
              "key": "Indication",
              "value": "Myeloid/Lymphoid Neoplasms (MLN) with FGFR1 rearrangement"
            },
            {
              "key": "NDA Submission Date",
              "value": "October 2021"
            },
            {
              "key": "NDA Withdrawal Date",
              "value": "January 2022"
            },
            {
              "key": "MAA Withdrawal Date",
              "value": "July 2022"
            },
            {
              "key": "FDA Designation",
              "value": "Orphan Drug Designation"
            },
            {
              "key": "Significant Trial",
              "value": "CITADEL clinical program"
            },
            {
              "key": "Key Molecule",
              "value": "parsaclisib"
            },
            {
              "key": "Indication for Parsaclisib",
              "value": "Autoimmune hemolytic anemia (AIHA)"
            },
            {
              "key": "FDA Designation",
              "value": "Orphan Drug Designation for AIHA"
            },
            {
              "key": "Completion Status",
              "value": "Ongoing trials for retifanlimab"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 18,
          "title": "Clinical Development Pipeline Summary",
          "data": [
            {
              "key": "treatment",
              "value": "ruxolitinib cream (JAKIU/JAK2) ruxolitinib cream +"
            },
            {
              "key": "indication_and_phase",
              "value": "Atopic dermatitis: Phase III pediatric study (TRuE-AD3)"
            },
            {
              "key": "treatment",
              "value": "ruxolitinib cream (JAKIU/JAK2) ruxolitinib cream +"
            },
            {
              "key": "indication_and_phase",
              "value": "Vitiligo: Phase III (TRuE-V1, TRuE-V2); approved by FDA; MAA under review"
            },
            {
              "key": "treatment",
              "value": "ruxolitinib cream (JAKIU/JAK2) ruxolitinib cream +"
            },
            {
              "key": "indication_and_phase",
              "value": "Lichen planus: Phase II"
            },
            {
              "key": "treatment",
              "value": "ruxolitinib cream (JAKIU/JAK2) ruxolitinib cream +"
            },
            {
              "key": "indication_and_phase",
              "value": "Lichen sclerosus: Phase I"
            },
            {
              "key": "treatment",
              "value": "ruxolitinib cream (JAKIU/JAK2) ruxolitinib cream +"
            },
            {
              "key": "indication_and_phase",
              "value": "Hidradenitis suppurativa: Phase II"
            },
            {
              "key": "treatment",
              "value": "ruxolitinib cream (JAKIU/JAK2) ruxolitinib cream +"
            },
            {
              "key": "indication_and_phase",
              "value": "Vitiligo: Phase II"
            },
            {
              "key": "treatment",
              "value": "phototherapy) povorcitinib (JAK1)"
            },
            {
              "key": "indication_and_phase",
              "value": "Hidradenitis suppurativa: Phase IIb; Phase III (STOP-HS1, STOP-HS2)"
            },
            {
              "key": "treatment",
              "value": "phototherapy) povorcitinib (JAK1)"
            },
            {
              "key": "indication_and_phase",
              "value": "Vitiligo: Phase II"
            },
            {
              "key": "treatment",
              "value": "phototherapy) povorcitinib (JAK1)"
            },
            {
              "key": "indication_and_phase",
              "value": "Prurigo nodularis: Phase II"
            },
            {
              "key": "treatment",
              "value": "auremolimab (anti-IL-15RB)"
            },
            {
              "key": "indication_and_phase",
              "value": "Vitiligo: Phase I in preparation"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 20,
          "title": "Regulatory Updates on Baricitinib",
          "data": [
            {
              "key": "Regulatory updates",
              "value": "In April 2021, the FDA extended the review period for the sNDA for baricitinib for moderate to severe AD by three months."
            },
            {
              "key": "FDA decision",
              "value": "In July 2021, the FDA will not meet the PDUFA action date for baricitinib for adult moderate to severe AD."
            },
            {
              "key": "January 2022 update",
              "value": "Lilly announced that alignment with the FDA on the indicated population had not yet been reached."
            },
            {
              "key": "European Commission approval",
              "value": "In October 2020, the European Commission approved baricitinib as OLUMIANT for moderate-to-severe AD."
            },
            {
              "key": "MHLW approval",
              "value": "In December 2020, baricitinib was approved by the MHLW for moderate-to-severe AD."
            },
            {
              "key": "Alopecia Areata designation",
              "value": "In March 2020, baricitinib received Breakthrough Therapy designation for alopecia areata."
            },
            {
              "key": "FDA EUA for COVID-19",
              "value": "In November 2020, the FDA issued an EUA for baricitinib for COVID-19 treatment."
            },
            {
              "key": "Broadened EUA",
              "value": "In July 2021, the EUA for baricitinib was broadened for treatment with or without remdesivir."
            },
            {
              "key": "COVID-19 approval",
              "value": "In June 2022, the FDA approved baricitinib as OLUMIANT for the treatment of COVID-19."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 30,
          "title": "FDA Approval Process and Challenges",
          "data": [
            {
              "key": "treatment_time",
              "value": "longer than anticipated treatment time required to demonstrate effectiveness or determine the appropriate product dose"
            },
            {
              "key": "supply_issues",
              "value": "lack of sufficient supplies of the drug candidate for use in clinical trials"
            },
            {
              "key": "medical_events",
              "value": "adverse medical events or side effects in treated patients"
            },
            {
              "key": "effectiveness_issues",
              "value": "lack of effectiveness of the drug candidate being tested"
            },
            {
              "key": "toxicity_warning",
              "value": "Any drug is likely to produce some toxicities or undesirable side effects in animals and in humans when administered at sufficiently high doses and/or for sufficiently long periods of time."
            },
            {
              "key": "FDA_programs",
              "value": "The FDA’s fast track, breakthrough therapy, accelerated approval, and priority review designation programs are intended to facilitate the development and expedite the review and approval of drug candidates."
            },
            {
              "key": "NDA_BLA_review",
              "value": "Sponsors submit the results of preclinical studies and clinical trials to the FDA as part of an NDA or BLA."
            },
            {
              "key": "priority_review",
              "value": "The FDA seeks to review NDAs and BLAs that are granted priority status more quickly than those given standard review status."
            },
            {
              "key": "approval_restrictions",
              "value": "FDA approval of a product can include restrictions on the product’s use or distribution."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 39,
          "title": "Coverage and Reimbursement Challenges for OPZELURA",
          "data": [
            {
              "key": "Significant consolidation",
              "value": "There has been significant consolidation in the health insurance industry."
            },
            {
              "key": "Negotiation with PBMs",
              "value": "Negotiating agreements with additional PBMs and payor accounts."
            },
            {
              "key": "Impact of formulary exclusions",
              "value": "Payors could decide to exclude OPZELURA from formulary coverage."
            },
            {
              "key": "Patient cost-sharing",
              "value": "An inability to maintain adequate formulary positions could increase patient cost-sharing."
            },
            {
              "key": "Impact on commercial viability",
              "value": "Health care reform measures could impact pricing and profitability."
            },
            {
              "key": "Risks from collaborators",
              "value": "Collaborators Novartis and Eli Lilly are affected by similar considerations."
            },
            {
              "key": "Dependence on pharmacies",
              "value": "Depend upon a limited number of specialty pharmacies and wholesalers."
            },
            {
              "key": "Distribution issues",
              "value": "Loss of specialty pharmacies could adversely affect operations."
            },
            {
              "key": "Inventory carrying",
              "value": "Specialty pharmacies expected to carry a very limited inventory."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 44,
          "title": "Risks Related to Competition and Public Health Epidemics",
          "data": [
            {
              "key": "ICLUSIG competition factors",
              "value": "Efficacy, cost, breadth of approved use, safety and side-effect profile."
            },
            {
              "key": "Generic versions of imatinib",
              "value": "Availability may impact commercialization of ICLUSIG."
            },
            {
              "key": "MONJUVI/MINJUVI competition factors",
              "value": "Efficacy, cost, breadth of approved use, safety and side-effect profile."
            },
            {
              "key": "PEMAZYRE competitors",
              "value": "Major pharmaceutical and biotechnology companies, specialty pharmaceutical firms."
            },
            {
              "key": "OPZELURA competitors",
              "value": "Over-the-counter topical treatments, prescription treatments, generic versions."
            },
            {
              "key": "COVID-19 impact on business",
              "value": "Adverse effects on operations, results of operations and financial condition."
            },
            {
              "key": "Research and development disruptions",
              "value": "Potential limitations in accessing laboratory space and conducting research."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 45,
          "title": "Impact of COVID-19 on Operations",
          "data": [
            {
              "key": "Sales and Marketing Disruptions",
              "value": "Sales and marketing activities limited by work from home orders, travel restrictions, and decreased patient visits."
            },
            {
              "key": "Clinical Trials Impact",
              "value": "Delays in clinical trials due to hospital resource prioritization for COVID-19 patients."
            },
            {
              "key": "Regulatory Disruptions",
              "value": "Regulatory agencies experiencing disruptions, affecting timelines for drug candidate applications."
            },
            {
              "key": "Supply Chain Challenges",
              "value": "Potential supply chain disruptions affecting ability to obtain materials for drug products."
            },
            {
              "key": "Financial Market Deterioration",
              "value": "Deterioration of credit and financial markets could impact cash holdings and accounts receivable."
            },
            {
              "key": "Uncertain Future Impacts",
              "value": "The ultimate impact of COVID-19 on business operations remains uncertain."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 48,
          "title": "Discontinuation of Clinical Trials and Regulatory Updates",
          "data": [
            {
              "key": "Trial Discontinuation",
              "value": "C-reactive protein trial was stopped early due to insufficient likelihood of meeting efficacy endpoint."
            },
            {
              "key": "Regulatory Challenges",
              "value": "FDA extended review period for NDA for ruxolitinib cream by three months."
            },
            {
              "key": "Complete Response Letter",
              "value": "FDA issued complete response letter for BLA of retifanlimab, stating additional data are needed."
            },
            {
              "key": "Health Care Reform Impact",
              "value": "U.S. government made significant changes impacting Medicare reimbursement and drug pricing."
            },
            {
              "key": "Inflation Reduction Act Provisions",
              "value": "Includes provisions for government price negotiation and rebate liabilities."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 49,
          "title": "Regulatory and Reimbursement Challenges",
          "data": [
            {
              "key": "Summary",
              "value": "Significant uncertainty regarding implementation of reforms affecting drug pricing and reimbursement."
            },
            {
              "key": "Impact on Sales",
              "value": "Reforms could significantly reduce net sales from Medicare programs."
            },
            {
              "key": "Future Investments",
              "value": "Changes may affect future investments in drug development."
            },
            {
              "key": "Legislative Interest",
              "value": "Increasing legislative and enforcement interest in drug pricing practices."
            },
            {
              "key": "Consequences of Regulations",
              "value": "Could impose downward pressure on prices, limiting commercial viability of products."
            },
            {
              "key": "Market Trends",
              "value": "Trend towards managed health care may lead to lower prices or rejection of products."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Economic effects of the pandemic may accelerate healthcare reform efforts, adversely affecting business."
            },
            {
              "key": "Regulatory Hearings",
              "value": "Possible investigations regarding pricing may incur significant expenses and distract from business operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 51,
          "title": "Collaborative Licensing and Development Challenges",
          "data": [
            {
              "key": "Summary",
              "value": "The company discusses challenges in establishing collaboration and licensing arrangements with other parties for drug development and commercialization."
            },
            {
              "key": "Potential Issues",
              "value": "May face complications due to negotiating complexities, competitor interest, or unfavorable terms in arrangements."
            },
            {
              "key": "Impact of Failed Agreements",
              "value": "Failure to establish these collaborations may adversely affect the company's operations and revenue."
            },
            {
              "key": "Specific Collaborations",
              "value": "Includes discussions on collaborations with Merus, Calithera Biosciences, and others."
            },
            {
              "key": "Case Example",
              "value": "Opted out of development with Merus on MCLA-145 and terminated collaboration with Calithera Biosciences in September 2022."
            },
            {
              "key": "Financial Implications",
              "value": "Contractual obligations may lead to significant upfront payments; unsuccessful candidates could adversely affect finance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 71,
          "title": "Revenue Recognition and Product Revenues",
          "data": [
            {
              "key": "Description",
              "value": "Product revenues consisting of sales of JAKAFI, OPZELURA, PEMAZYRE, ICLUSIG, and MINJUVI, recognized upon satisfying performance obligation."
            },
            {
              "key": "Customer Credits",
              "value": "Customers are offered allowances, service fees, and prompt payment discounts, deducted from total product sales."
            },
            {
              "key": "Rebates and Discounts",
              "value": "Accruals for mandated discounts under Medicaid Drug Rebate Program and in Europe, based on statutory rates and historical data."
            },
            {
              "key": "Impact of Sales Allowances",
              "value": "A 5% change in sales allowance and accruals would impact income before taxes by approximately $50.1 million as of Dec 31, 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 72,
          "title": "Adjustments to Revenue Estimates and Accruals",
          "data": [
            {
              "key": "Chargebacks Description",
              "value": "Discounts that occur when certain indirect contracted customers purchase directly from wholesalers."
            },
            {
              "key": "Medicare Part D Coverage Gap",
              "value": "Manufacturers must fund 70% of the Medicare Part D insurance coverage gap for prescription drugs."
            },
            {
              "key": "Co-payment Assistance",
              "value": "Accrual liability based on actual program participation and estimates of program redemption."
            },
            {
              "key": "Product Royalty Revenues",
              "value": "Royalty revenues estimated based on information provided by manufacturers."
            },
            {
              "key": "Milestone and Contract Revenues",
              "value": "Transaction price determined by estimating variable consideration including milestone payments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 88,
          "title": "Cash Flow Statement",
          "data": [
            {
              "key": "Cash flows from operating activities",
              "value": "Net cash provided by (used in) operating activities (2022: $969,941, 2021: $749,488, 2020: -$124,599)"
            },
            {
              "key": "Net cash used in investing activities",
              "value": "Net cash used in investing activities (2022: -$78,542, 2021: -$207,699, 2020: -$269,001)"
            },
            {
              "key": "Net cash (used in) provided by financing activities",
              "value": "Net cash (used in) provided by financing activities (2022: -$794, 2021: $6,176, 2020: $71,709)"
            },
            {
              "key": "Cash position",
              "value": "Cash, cash equivalents, and restricted cash at end of period (2022: $2,953,120, 2021: $2,059,160, 2020: $1,514,765)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 91,
          "title": "Lease Accounting and Impairment of Long-Lived Assets",
          "data": [
            {
              "key": "Lease Accounting Policy",
              "value": "All leases with a term greater than 12 months are recorded as obligations on the balance sheet."
            },
            {
              "key": "Right-of-use Assets Valuation",
              "value": "Valued at the initial measurement of the lease liability, plus initial direct costs, minus lease incentives."
            },
            {
              "key": "Goodwill Impairment Testing",
              "value": "Goodwill is tested for impairment at least annually as of October 1."
            },
            {
              "key": "Income Taxes Recognition",
              "value": "Deferred tax assets and liabilities recognized for expected future tax consequences of temporary differences."
            },
            {
              "key": "Valuation Allowance Release",
              "value": "Released on the majority of U.S. deferred tax assets as of December 31, 2021."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 94,
          "title": "Revenue Recognition Related to Collaborative Arrangements",
          "data": [
            {
              "key": "Revenue Recognition Principles",
              "value": "Management assesses if variable consideration will be constrained based on factors outside the Company's control."
            },
            {
              "key": "Performance Obligations",
              "value": "Amounts allocated to performance obligations based on relative standalone selling prices."
            },
            {
              "key": "Intellectual Property Licensing",
              "value": "Out-licensing rights considered distinct are recognized based on functionality."
            },
            {
              "key": "Milestone Revenues",
              "value": "Milestones recognized upon satisfaction of developmental or regulatory events."
            },
            {
              "key": "Collaboration Agreements",
              "value": "Uncertainty in milestone events leads to their exclusion until confirmed."
            },
            {
              "key": "Risk in Discovery Process",
              "value": "Recognition of revenue from milestone payments occurs upon achievement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 122,
          "title": "Opinion on Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Company",
              "value": "Incyte Corporation"
            },
            {
              "key": "Audit Opinion Date",
              "value": "February 7, 2023"
            },
            {
              "key": "Audit Basis",
              "value": "Public Company Accounting Oversight Board standards"
            },
            {
              "key": "Reporting Period End Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Internal Control Framework",
              "value": "COSO criteria"
            },
            {
              "key": "Audit Firm",
              "value": "Ernst & Young LLP"
            },
            {
              "key": "Location of Audit Firm",
              "value": "Philadelphia, Pennsylvania"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 28,
          "title": "Regulatory Review and Approval Process",
          "data": [
            {
              "key": "Regulatory Approvals",
              "value": "obtain required regulatory approvals"
            },
            {
              "key": "Manufacturing and Marketing",
              "value": "manufacture, market, distribute and sell products developed"
            },
            {
              "key": "Drug Pricing Concerns",
              "value": "suggestions for low-cost drugs in developing countries"
            },
            {
              "key": "Patent Enforcement Concerns",
              "value": "potential non-enforceability of patents against generic competition"
            },
            {
              "key": "Government Regulation",
              "value": "ongoing R&D activities subject to extensive regulation"
            },
            {
              "key": "FDA Requirements",
              "value": "lengthy and uncertain regulatory review process"
            },
            {
              "key": "Preclinical Testing",
              "value": "laboratory testing, animal studies, formulation studies"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 31,
          "title": "Regulatory Requirements for Drug Approval and Marketing",
          "data": [
            {
              "key": "Approval Requirements",
              "value": "Approval may entail requirements for post-marketing studies or risk evaluation and mitigation strategies."
            },
            {
              "key": "FDA Authority",
              "value": "The FDA may deny approval of an NDA or BLA or may issue a complete response."
            },
            {
              "key": "Orphan Drug Act Incentives",
              "value": "Provides incentives to develop and market drugs for rare diseases."
            },
            {
              "key": "Continual Regulation",
              "value": "A marketed product is subject to continual review and periodic inspections by the FDA."
            },
            {
              "key": "GMP Compliance",
              "value": "We and our third-party manufacturers must comply with Good Manufacturing Practices."
            },
            {
              "key": "Post-Approval Regulation",
              "value": "Products are subject to continuing regulation by the FDA including record-keeping and reporting of adverse experiences."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 32,
          "title": "Adverse Event Reporting and Regulatory Compliance",
          "data": [
            {
              "key": "Compliance Issues",
              "value": "FDA's guidelines on adverse events reporting and PDMA compliance"
            },
            {
              "key": "State Regulations",
              "value": "States impose registration requirements for pharmaceutical product distributors"
            },
            {
              "key": "Marketing Challenges",
              "value": "Compliance with local regulations may hinder marketing efforts"
            },
            {
              "key": "FDA Inspection",
              "value": "Receive notice of inspectional observations during FDA inspections"
            },
            {
              "key": "Exclusivity Periods",
              "value": "FDA grants exclusivity for NDAs and pediatric exclusivity"
            },
            {
              "key": "Foreign Regulation",
              "value": "Marketing contingent upon approval from foreign regulatory authorities"
            },
            {
              "key": "Clinical Trials",
              "value": "Clinical trial application (CTA) required before trials in non-US countries"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 33,
          "title": "Regulatory Approval Processes",
          "data": [
            {
              "key": "Centralized Procedure",
              "value": "Easier marketing authorizations across the EU with a maximum evaluation time of 210 days."
            },
            {
              "key": "Mutual Recognition Procedure (MRP)",
              "value": "Facilitates individual national marketing authorizations within the EU based on reference member states."
            },
            {
              "key": "Orphan Drug Legislation in the EU",
              "value": "Available for therapies addressing conditions affecting five or fewer per 10,000 persons, with ten years of market exclusivity."
            },
            {
              "key": "Consequences of Non-compliance",
              "value": "May result in fines, suspension of clinical trials, withdrawal of regulatory approvals, and more."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 40,
          "title": "Regulatory Challenges and Commercialization Risks",
          "data": [
            {
              "key": "Issue",
              "value": "Potential loss of large specialty pharmacy or wholesaler affecting revenue"
            },
            {
              "key": "Impact",
              "value": "Could materially and adversely affect results of operations and financial condition"
            },
            {
              "key": "Regulatory oversight",
              "value": "Subject to rigorous regulation by FDA and other agencies after product marketing approval"
            },
            {
              "key": "Approval status",
              "value": "Risk of losing approval to market products if regulations not complied with"
            },
            {
              "key": "Update on warnings",
              "value": "FDA labeling update for JAKAFI includes warnings of risks related to cardiovascular events"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 41,
          "title": "Regulatory Risks Associated with JAKAFI and OPZELURA",
          "data": [
            {
              "key": "Potential Risks from FDA Non-Compliance",
              "value": "Failure to comply with the laws and regulations administered by the FDA could result in sanctions, fines, suspension of regulatory approval, and other penalties."
            },
            {
              "key": "Product Liability Risks",
              "value": "Side effects and complications from the use of JAKAFI, ICLUSIG, PEMAZYRE, MONJUVI/MINJUVI, and OPZELURA expose the company to product liability claims."
            },
            {
              "key": "Consequences of Regulatory Approvals",
              "value": "Revocation or negative impacts on regulatory approvals may occur due to harmful perceptions of products."
            },
            {
              "key": "Impact of Unknown Risks",
              "value": "New risks or side effects discovered from off-label uses may adversely affect market approval or necessitate product recalls."
            },
            {
              "key": "Market Implications",
              "value": "The occurrence of product liability claims can harm reputation and sales, leading to increased commercialization costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 42,
          "title": "Regulatory and Legal Compliance Risks",
          "data": [
            {
              "key": "Health Risks",
              "value": "Life-threatening health risks during treatment may involve litigation."
            },
            {
              "key": "Investor Responsibility",
              "value": "Investigation into adverse events could impact commercialization efforts."
            },
            {
              "key": "Legal Compliance",
              "value": "Compliance with FDAs and anti-kickback laws is crucial."
            },
            {
              "key": "Off-label Promotion",
              "value": "Manufacturers are prohibited from promoting off-label uses."
            },
            {
              "key": "Consequences of Violations",
              "value": "Potential for regulatory enforcement actions and significant fines."
            },
            {
              "key": "Sales Impact",
              "value": "Marketing compliance may be impacted by local laws."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 47,
          "title": "Regulatory Approval Requirements",
          "data": [
            {
              "key": "Risk Factors",
              "value": "If we or our collaborators are unable to obtain regulatory approval for our drug candidates in the United States and foreign jurisdictions, we or our collaborators will not be permitted to commercialize products resulting from our research."
            },
            {
              "key": "Regulatory Process Description",
              "value": "To obtain regulatory approval, we or our collaborators must first show that our or our collaborators' drug candidates are safe and effective for target indications through preclinical testing and clinical trials."
            },
            {
              "key": "Challenges",
              "value": "Completion of clinical trials may take several years and failure may occur at any stage of testing."
            },
            {
              "key": "Recent Approval Example",
              "value": "In June 2018, after a resubmission of the NDA, the FDA approved the 2mg dose of OLUMIANT for the treatment of adults with moderately-to-severely active rheumatoid arthritis."
            },
            {
              "key": "Withdrawal Example",
              "value": "In January 2022, we announced that we withdrew the NDA seeking approval of parsaclisib."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 54,
          "title": "Regulatory Risks and Manufacturing Challenges",
          "data": [
            {
              "key": "Regulatory Authority Actions",
              "value": "Halting clinical trials and regulatory approval of drug products."
            },
            {
              "key": "Manufacturing Difficulties",
              "value": "Challenges with scaling production, quality control, and maintaining supply."
            },
            {
              "key": "Geopolitical Risks",
              "value": "Potential supply chain disruptions due to events such as COVID-19 and geopolitical tensions."
            },
            {
              "key": "Single Source Dependency",
              "value": "Reliance on a limited number of suppliers for crucial materials."
            },
            {
              "key": "Regulatory Compliance Risks",
              "value": "Risks associated with manufacturing and health care regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 55,
          "title": "Regulatory and Legal Challenges in Pharmaceutical Industry",
          "data": [
            {
              "key": "Regulatory Agencies",
              "value": "FDA and comparable agencies regulate critical business activities including preclinical and clinical studies, product manufacturing, advertising, distribution."
            },
            {
              "key": "Lawsuits and Investigations",
              "value": "Pharmaceutical companies face lawsuits alleging violations such as incorrect pricing information, improper promotion, and submission of false claims."
            },
            {
              "key": "Civil Investigative Demand",
              "value": "In December 2018, a civil investigative demand for documents relating to speaker and patient assistance programs was received from the DOJ."
            },
            {
              "key": "Settlement Amount",
              "value": "The company agreed to settle with the DOJ for $12.6 million in May 2021."
            },
            {
              "key": "Risks",
              "value": "Risks include damages, fines, penalties, and potential repayment of government funds."
            },
            {
              "key": "Counterfeit Products",
              "value": "Concerns over counterfeit products undermining reputation and business."
            },
            {
              "key": "Headquarters and Operations",
              "value": "The company's operations are mainly in Wilmington, Delaware, and loss of access to this facility would negatively impact the business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 61,
          "title": "Risks Relating to Intellectual Property and Legal Matters",
          "data": [
            {
              "key": "Revenue Sources",
              "value": "Royalties, milestone payments and other payments under collaboration agreements."
            },
            {
              "key": "Revenue Risks",
              "value": "Dependency on achieving milestones, developing product candidates, renewing or entering into new collaborations."
            },
            {
              "key": "Significant Products",
              "value": "JAKAVI and OLUMIANT product royalties."
            },
            {
              "key": "Intellectual Property Risks",
              "value": "Potential infringement claims on technologies and products."
            },
            {
              "key": "Legal Proceedings",
              "value": "Possibility of arbitration, litigation, and claims disrupting drug discovery efforts."
            },
            {
              "key": "Management Attention",
              "value": "Notices from third parties could divert management’s focus from drug development."
            },
            {
              "key": "Future Legal Actions",
              "value": "Potential lawsuits regarding patent infringement or contract violations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 64,
          "title": "Data Security Breaches and Regulatory Compliance Risks",
          "data": [
            {
              "key": "data_security_breach_risks",
              "value": "Enhancements to IT systems may not lead to productivity improvements and pose data security vulnerabilities."
            },
            {
              "key": "potential_impacts",
              "value": "Loss of confidential information, trade secrets, reputational harm, identity theft."
            },
            {
              "key": "regulatory_enforcement",
              "value": "Potential enforcement actions by U.S. states, Federal government, and foreign governments under data privacy laws."
            },
            {
              "key": "gdpr_penalties",
              "value": "Fines of up to €20 million or 4% of annual global revenues for GDPR violations."
            },
            {
              "key": "uk_gdpr_penalties",
              "value": "Potential fines of up to £17.5 million or 4% of annual global revenue."
            },
            {
              "key": "ccpa_provisions",
              "value": "The California Consumer Privacy Act grants private rights of action for data breaches."
            },
            {
              "key": "social_media_risks",
              "value": "Increased use of social media could lead to liability or reputational damage."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 121,
          "title": "Management's Assessment of Internal Control Over Financial Reporting",
          "data": [
            {
              "key": "CEO and CFO Evaluation",
              "value": "Concluded that controls were effective at reasonable assurance level."
            },
            {
              "key": "Changes in Internal Control",
              "value": "No changes that materially affected financial reporting."
            },
            {
              "key": "Audit by",
              "value": "Ernst & Young LLP"
            },
            {
              "key": "Framework Used",
              "value": "Internal Control — Integrated Framework (2013)"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": false,
      "elements": []
    },
    "has_supply_chain_disruptions": {
      "value": true,
      "elements": [
        {
          "type": "supply_chain_disruption",
          "page": 34,
          "title": "Supply Chain and Quality Assurance for Drug Manufacturing",
          "data": [
            {
              "key": "Manufacturing Facilities",
              "value": "Do not operate manufacturing facilities for clinical or commercial production of JAKAFI, ICLUSIG, PEMAZYRE, OPZELURA and MONJUVI/MINJUVI."
            },
            {
              "key": "Reliance on Third Parties",
              "value": "Expect to continue to rely on third parties for the manufacture of commercial supplies of raw materials, API and finished drug product."
            },
            {
              "key": "Yverdon Facility",
              "value": "Purchased land in Yverdon, Switzerland for construction of a large molecule production facility."
            },
            {
              "key": "Construction and Licensing",
              "value": "Construction commenced July 2018; GMP license granted by Swissmedic in June 2022."
            },
            {
              "key": "Manufacturing Start Date",
              "value": "Started production of MONJUVI/MINJUVI drug substance during the fourth quarter of 2022."
            },
            {
              "key": "Regulatory Approval",
              "value": "Expected regulatory approval for the European market in Q1 2024 and Q4 2024 in the U.S."
            },
            {
              "key": "Supply Chain Complexity",
              "value": "Multi-step international process requiring significant financial commitment."
            },
            {
              "key": "Relationships with Third Parties",
              "value": "Contractual relationships with multiple third-party manufacturers for API and drug products."
            },
            {
              "key": "Risks of Supply Limitations",
              "value": "Possible inability to obtain sufficient quantities of raw materials or finished products from suppliers."
            },
            {
              "key": "Quality Assurance Program",
              "value": "Program to ensure compliance with FDA and EMA Good Manufacturing Practices."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 26,
          "title": "Drug Patent Estate Status and Expiration Dates by Region",
          "data": [
            {
              "key": "Drug/Drug Candidate (Target)",
              "value": "pemigatinib (FGFR)"
            },
            {
              "key": "Status of U.S. Composition of Matter Patent Estate",
              "value": "Granted and pending (2035)°"
            },
            {
              "key": "Status of EU Composition of Matter Patent Estate",
              "value": "Granted and pending (2033)"
            },
            {
              "key": "Status of Japan Composition Matter Patent Estate",
              "value": "Granted and pending (2036)"
            },
            {
              "key": "Drug/Drug Candidate (Target)",
              "value": "ponatinib (BCRABL)"
            },
            {
              "key": "Status of U.S. Composition of Matter Patent Estate",
              "value": ""
            },
            {
              "key": "Status of EU Composition of Matter Patent Estate",
              "value": "Granted and pending (2026)"
            },
            {
              "key": "Status of Japan Composition Matter Patent Estate",
              "value": ""
            },
            {
              "key": "Drug/Drug Candidate (Target)",
              "value": "retifanlimab (PD-1)©"
            },
            {
              "key": "Status of U.S. Composition of Matter Patent Estate",
              "value": "Granted and pending (2036)"
            },
            {
              "key": "Status of EU Composition of Matter Patent Estate",
              "value": "Granted and pending (2036)"
            },
            {
              "key": "Status of Japan Composition Matter Patent Estate",
              "value": "Granted and pending (2036)"
            },
            {
              "key": "Drug/Drug Candidate (Target)",
              "value": "tafasitamab (CD19)"
            },
            {
              "key": "Status of U.S. Composition of Matter Patent Estate",
              "value": "Granted and pending (2029)°"
            },
            {
              "key": "Status of EU Composition of Matter Patent Estate",
              "value": "Granted (2027)"
            },
            {
              "key": "Status of Japan Composition Matter Patent Estate",
              "value": "Granted (2027)"
            },
            {
              "key": "Drug/Drug Candidate (Target)",
              "value": "axatilimab (CSF-IR)®"
            },
            {
              "key": "Status of U.S. Composition of Matter Patent Estate",
              "value": "Granted (2034)"
            },
            {
              "key": "Status of EU Composition of Matter Patent Estate",
              "value": "Granted and pending (2034)"
            },
            {
              "key": "Status of Japan Composition Matter Patent Estate",
              "value": "Granted and pending (2034)"
            },
            {
              "key": "summary",
              "value": "This table provides patent expiration information for various drug candidates across three major markets (US, EU, and Japan). The patents extend from 2026 to 2036, with retifanlimab having the latest expiration date (2036) across all regions. Most drugs have either granted or pending patent status, with some variations between regions. Notable is ponatinib, which only shows patent information for the EU market expiring in 2026."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 36,
          "title": "Employee Policies and Diversity Initiatives",
          "data": [
            {
              "key": "Harassment Policy",
              "value": "Prohibit harassment of all kinds."
            },
            {
              "key": "Retaliation Policy",
              "value": "Prohibit retaliation in all forms."
            },
            {
              "key": "Diversity Initiatives",
              "value": "Inclusion Committee led by CEO and CHRO to implement actionable plans."
            },
            {
              "key": "Recruitment Goal",
              "value": "70% of open positions in the US to include Black or Hispanic candidates."
            },
            {
              "key": "Compensation Package",
              "value": "Competitive compensation, annual incentive compensation plan, and equity-based grants."
            },
            {
              "key": "Health Insurance Coverage",
              "value": "100% coverage for full-time employees; 95% subsidized for part-time employees."
            },
            {
              "key": "Professional Development",
              "value": "Opportunities for growth, tuition reimbursement for full-time employees."
            },
            {
              "key": "Employee Growth",
              "value": "Employee count growth by 11% in 2022."
            },
            {
              "key": "Gender Diversity",
              "value": "52% female and 48% male employees."
            }
          ],
          "currency": "N/A"
        }
      ]
    }
  },
  "currency": {
    "USD": 3,
    "EUR": 42,
    "AUD": 3,
    "CAD": 7,
    "ZAR": 1
  },
  "sha1": "4d3e52b69b4b5366e54ce87cf641b01b1419bdee"
}